Apatinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Apatinib comprises 690 peer-reviewed publications across 15 journals, 54 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Breast Neoplasms, Stomach Neoplasms, Neoplasm Metastasis, and Carcinoma, Hepatocellular. Most recent publication: Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial., J Clin Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH, van Tinteren H, May A, et al. · Lancet · 2015
    PubMed: PMID 25862517 · NCT02829385 · Colorectal Neoplasms
  2. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A, Trusolino L, Martino C, et al. · Lancet Oncol · 2017
    PubMed: PMID 27108243 · NCT03225937 (HERACLES) · Colorectal Neoplasms
  3. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
    Qin S, Ren Z, Meng Z, et al. · Lancet Oncol · 2020
    PubMed: PMID 32112738 · NCT04642664 (ACABC) · Cholangiocarcinoma
  4. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S, Chen B, Burugu S, et al. · JAMA Oncol · 2017
    PubMed: PMID 28750133 · NCT00667251 · Breast Neoplasms
  5. Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?
    Franses JW, Hong TS, Zhu AX, et al. · Lancet Gastroenterol Hepatol · 2020
    PubMed: PMID 31109809 · NCT04642664 (ACABC) · Cholangiocarcinoma
  6. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Fehm T, Cottone F, Dunton K, et al. · Lancet Oncol · 2024
    PubMed: PMID 38697155 · NCT03523585 · Breast Neoplasms
  7. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
    Blay JY, Chevret S, Le Cesne A, et al. · Lancet Oncol · 2023
    PubMed: PMID 37429302 · NCT06140732 · Chordoma
  8. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    André F, Hee Park Y, Kim SB, et al. · Lancet · 2023
    PubMed: PMID 37086745 · NCT03523585 · Breast Neoplasms

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00073528Breast NeoplasmsNumber of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced or Metastatic Breast Cancer as Assessed by the Investigator
From the date of randomization until the date of the first documented progression or date of death from any cause, whichever came first, assessed for up to 46 months
Lapatinib 1500 mg + Letrozole 2.5 mg88 Participants
Placebo + Letrozole 2.5 mg89 Participants
NCT00073528Breast NeoplasmsProgression Free Survival (PFS) of Participants in the HER2-Positive Population as Assessed by the Investigator
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 46 months
Lapatinib 1500 mg + Letrozole 2.5 mg35.4 Weeks
Placebo + Letrozole 2.5 mg13.0 Weeks
NCT00075270Breast NeoplasmsTime to Progression as Evaluated by the Independent Review Committee (IRC)
Randomization until the date of disease progression or death (average of 26 weeks)
Lapatinib With Paclitaxel33.7 weeks
Placebo With Paclitaxel26.1 weeks
NCT00075270Breast NeoplasmsTime to Progression as Evaluated by the Investigator
Randomization until the date of disease progression or death (average of 26 weeks)
Lapatinib With Paclitaxel29.0 weeks
Placebo With Paclitaxel22.9 weeks
NCT00272987Breast NeoplasmsChange From Baseline in Body Temperature at the Indicated Time Points
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.100 Degree Celsius (±0.9083 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.011 Degree Celsius (±0.5250 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.021 Degree Celsius (±0.4374 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.052 Degree Celsius (±0.5814 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.018 Degree Celsius (±0.5712 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.157 Degree Celsius (±0.5006 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.094 Degree Celsius (±0.4956 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.156 Degree Celsius (±0.6077 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.215 Degree Celsius (±0.5728 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.045 Degree Celsius (±0.4634 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.182 Degree Celsius (±0.4729 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.109 Degree Celsius (±0.4571 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.222 Degree Celsius (±1.0616 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1.300 Degree Celsius (±NA Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.067 Degree Celsius (±0.5610 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.150 Degree Celsius (±0.6442 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.450 Degree Celsius (±1.3435 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.017 Degree Celsius (±0.4834 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.057 Degree Celsius (±0.7390 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.000 Degree Celsius (±1.2728 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.286 Degree Celsius (±0.6744 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.150 Degree Celsius (±1.2021 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.200 Degree Celsius (±1.4142 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.167 Degree Celsius (±0.8083 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.092 Degree Celsius (±0.6238 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.200 Degree Celsius (±0.4359 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.083 Degree Celsius (±0.6833 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.250 Degree Celsius (±0.6403 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.050 Degree Celsius (±0.5000 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.080 Degree Celsius (±0.6099 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.160 Degree Celsius (±0.7436 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.700 Degree Celsius (±NA Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.229 Degree Celsius (±0.5062 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.125 Degree Celsius (±0.4573 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.200 Degree Celsius (±0.8155 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.080 Degree Celsius (±0.4662 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.267 Degree Celsius (±0.4131 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.111 Degree Celsius (±0.6489 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.070 Degree Celsius (±0.5889 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.550 Degree Celsius (±0.0707 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.020 Degree Celsius (±0.4367 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.129 Degree Celsius (±0.3946 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.314 Degree Celsius (±0.1952 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.242 Degree Celsius (±0.3605 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.217 Degree Celsius (±0.3920 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.400 Degree Celsius (±0.5074 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.200 Degree Celsius (±0.1414 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.240 Degree Celsius (±0.6427 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.340 Degree Celsius (±0.3286 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.225 Degree Celsius (±0.2754 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.150 Degree Celsius (±0.1732 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.127 Degree Celsius (±0.4880 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.400 Degree Celsius (±NA Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.238 Degree Celsius (±0.4138 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.567 Degree Celsius (±0.4960 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.100 Degree Celsius (±0.4138 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.529 Degree Celsius (±0.4751 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.154 Degree Celsius (±0.4294 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.237 Degree Celsius (±0.2134 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.300 Degree Celsius (±0.3536 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.300 Degree Celsius (±NA Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.450 Degree Celsius (±0.9192 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.017 Degree Celsius (±0.5193 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.247 Degree Celsius (±0.4652 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.140 Degree Celsius (±0.5320 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.300 Degree Celsius (±0.3536 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.121 Degree Celsius (±0.5494 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.250 Degree Celsius (±0.0707 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.000 Degree Celsius (±0.2000 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.237 Degree Celsius (±0.5999 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.173 Degree Celsius (±0.4636 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.533 Degree Celsius (±0.3786 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.078 Degree Celsius (±0.5976 Standard Deviation)
NCT00272987Breast NeoplasmsChange From Baseline in Heart Rate at the Indicated Time Points
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-4.667 Beats per minute (BPM) (±14.5717 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.800 Beats per minute (BPM) (±14.4810 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.500 Beats per minute (BPM) (±16.6463 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.714 Beats per minute (BPM) (±21.0295 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-8.286 Beats per minute (BPM) (±21.1638 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-4.667 Beats per minute (BPM) (±16.1245 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.600 Beats per minute (BPM) (±13.3766 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.000 Beats per minute (BPM) (±13.4907 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-1.889 Beats per minute (BPM) (±14.4866 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-5.500 Beats per minute (BPM) (±8.1955 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.000 Beats per minute (BPM) (±11.1624 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-1.000 Beats per minute (BPM) (±14.1614 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-5.000 Beats per minute (BPM) (±13.0128 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-4.933 Beats per minute (BPM) (±16.6496 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-4.313 Beats per minute (BPM) (±16.0155 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.476 Beats per minute (BPM) (±16.7768 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.478 Beats per minute (BPM) (±13.4667 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.217 Beats per minute (BPM) (±10.7109 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-1.714 Beats per minute (BPM) (±10.9099 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-5.667 Beats per minute (BPM) (±14.7908 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg9.200 Beats per minute (BPM) (±21.1234 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2.200 Beats per minute (BPM) (±24.6110 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.400 Beats per minute (BPM) (±10.1390 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-8.250 Beats per minute (BPM) (±7.6322 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-6.750 Beats per minute (BPM) (±13.1751 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-6.800 Beats per minute (BPM) (±15.3525 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-8.750 Beats per minute (BPM) (±6.4485 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.667 Beats per minute (BPM) (±15.0444 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-7.667 Beats per minute (BPM) (±9.4516 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-5.333 Beats per minute (BPM) (±13.2035 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1.000 Beats per minute (BPM) (±21.2132 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-4.000 Beats per minute (BPM) (±14.1421 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-4.000 Beats per minute (BPM) (±15.5563 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.500 Beats per minute (BPM) (±16.2635 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3.000 Beats per minute (BPM) (±NA Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg6.000 Beats per minute (BPM) (±NA Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-1.435 Beats per minute (BPM) (±19.3481 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.560 Beats per minute (BPM) (±13.1564 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.417 Beats per minute (BPM) (±15.6812 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.571 Beats per minute (BPM) (±17.6149 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-7.889 Beats per minute (BPM) (±17.3526 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-5.000 Beats per minute (BPM) (±17.9778 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2.625 Beats per minute (BPM) (±15.1369 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.500 Beats per minute (BPM) (±12.9422 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg4.857 Beats per minute (BPM) (±18.4791 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.000 Beats per minute (BPM) (±11.8533 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.000 Beats per minute (BPM) (±15.2151 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1.500 Beats per minute (BPM) (±15.0222 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.000 Beats per minute (BPM) (±15.3840 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1.000 Beats per minute (BPM) (±25.4558 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg19.000 Beats per minute (BPM) (±NA Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-5.300 Beats per minute (BPM) (±15.1808 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.417 Beats per minute (BPM) (±26.3593 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-1.429 Beats per minute (BPM) (±17.7281 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.231 Beats per minute (BPM) (±16.8481 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.500 Beats per minute (BPM) (±11.1098 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-7.900 Beats per minute (BPM) (±19.3990 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg3.600 Beats per minute (BPM) (±8.5615 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg7.750 Beats per minute (BPM) (±9.8814 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg3.333 Beats per minute (BPM) (±12.1268 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg5.353 Beats per minute (BPM) (±10.7642 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-2.875 Beats per minute (BPM) (±10.6074 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-1.917 Beats per minute (BPM) (±10.9084 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg5.167 Beats per minute (BPM) (±10.2843 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg13.200 Beats per minute (BPM) (±11.6060 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0.333 Beats per minute (BPM) (±10.5987 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg7.000 Beats per minute (BPM) (±11.5326 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-2.500 Beats per minute (BPM) (±9.1924 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-0.500 Beats per minute (BPM) (±10.6066 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-14.000 Beats per minute (BPM) (±NA Standard Deviation)
NCT00272987Breast NeoplasmsChange From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at the Indicated Time Points
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.0 Millimeter of mercury (mmHg) (±5.89 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3.2 Millimeter of mercury (mmHg) (±18.46 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1.6 Millimeter of mercury (mmHg) (±15.85 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg7.1 Millimeter of mercury (mmHg) (±13.25 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-7.7 Millimeter of mercury (mmHg) (±12.27 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-14.5 Millimeter of mercury (mmHg) (±4.95 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.5 Millimeter of mercury (mmHg) (±16.29 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg4.6 Millimeter of mercury (mmHg) (±12.35 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.8 Millimeter of mercury (mmHg) (±18.10 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1.7 Millimeter of mercury (mmHg) (±17.80 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2.9 Millimeter of mercury (mmHg) (±13.87 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2.3 Millimeter of mercury (mmHg) (±19.10 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3.2 Millimeter of mercury (mmHg) (±23.11 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.2 Millimeter of mercury (mmHg) (±24.44 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2.7 Millimeter of mercury (mmHg) (±14.47 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg6.5 Millimeter of mercury (mmHg) (±18.76 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg7.7 Millimeter of mercury (mmHg) (±14.47 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg8.4 Millimeter of mercury (mmHg) (±13.53 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg9.3 Millimeter of mercury (mmHg) (±22.07 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3.5 Millimeter of mercury (mmHg) (±16.53 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.1 Millimeter of mercury (mmHg) (±10.71 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg4.5 Millimeter of mercury (mmHg) (±12.96 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg8.7 Millimeter of mercury (mmHg) (±6.92 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg7.0 Millimeter of mercury (mmHg) (±20.20 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.7 Millimeter of mercury (mmHg) (±16.32 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg10.4 Millimeter of mercury (mmHg) (±16.59 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.5 Millimeter of mercury (mmHg) (±4.12 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg10.8 Millimeter of mercury (mmHg) (±7.53 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg7.0 Millimeter of mercury (mmHg) (±16.00 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg4.6 Millimeter of mercury (mmHg) (±7.89 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg12.3 Millimeter of mercury (mmHg) (±10.72 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg9.3 Millimeter of mercury (mmHg) (±15.22 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg13.3 Millimeter of mercury (mmHg) (±19.86 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg7.3 Millimeter of mercury (mmHg) (±8.50 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-11.0 Millimeter of mercury (mmHg) (±9.90 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-10.5 Millimeter of mercury (mmHg) (±10.61 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-4.0 Millimeter of mercury (mmHg) (±18.38 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg4.5 Millimeter of mercury (mmHg) (±23.33 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg10.0 Millimeter of mercury (mmHg) (±0 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg25.0 Millimeter of mercury (mmHg) (±NA Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.5 Millimeter of mercury (mmHg) (±16.13 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2.4 Millimeter of mercury (mmHg) (±19.18 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.5 Millimeter of mercury (mmHg) (±10.36 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.6 Millimeter of mercury (mmHg) (±11.41 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.3 Millimeter of mercury (mmHg) (±10.19 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.4 Millimeter of mercury (mmHg) (±12.98 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.0 Millimeter of mercury (mmHg) (±12.65 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-1.2 Millimeter of mercury (mmHg) (±11.30 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-1.8 Millimeter of mercury (mmHg) (±14.27 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.2 Millimeter of mercury (mmHg) (±13.70 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-7.2 Millimeter of mercury (mmHg) (±6.48 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-9.3 Millimeter of mercury (mmHg) (±11.36 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-9.0 Millimeter of mercury (mmHg) (±6.59 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.9 Millimeter of mercury (mmHg) (±7.57 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-7.4 Millimeter of mercury (mmHg) (±13.46 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-5.1 Millimeter of mercury (mmHg) (±8.62 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.6 Millimeter of mercury (mmHg) (±11.56 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-11.0 Millimeter of mercury (mmHg) (±6.40 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3.0 Millimeter of mercury (mmHg) (±9.26 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-4.8 Millimeter of mercury (mmHg) (±5.00 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.5 Millimeter of mercury (mmHg) (±5.58 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-5.8 Millimeter of mercury (mmHg) (±9.50 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-9.3 Millimeter of mercury (mmHg) (±11.48 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.8 Millimeter of mercury (mmHg) (±5.26 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-7.3 Millimeter of mercury (mmHg) (±6.29 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-4.4 Millimeter of mercury (mmHg) (±6.50 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-4.6 Millimeter of mercury (mmHg) (±9.10 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-8.5 Millimeter of mercury (mmHg) (±9.33 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-6.0 Millimeter of mercury (mmHg) (±7.94 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-6.0 Millimeter of mercury (mmHg) (±6.00 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-12.5 Millimeter of mercury (mmHg) (±0.71 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-17.0 Millimeter of mercury (mmHg) (±4.24 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-7.5 Millimeter of mercury (mmHg) (±10.61 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.0 Millimeter of mercury (mmHg) (±0 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1.0 Millimeter of mercury (mmHg) (±NA Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.5 Millimeter of mercury (mmHg) (±11.39 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.8 Millimeter of mercury (mmHg) (±11.96 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.0 Millimeter of mercury (mmHg) (±12.33 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-5.7 Millimeter of mercury (mmHg) (±20.38 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.4 Millimeter of mercury (mmHg) (±7.99 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-1.8 Millimeter of mercury (mmHg) (±11.81 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-11.5 Millimeter of mercury (mmHg) (±14.69 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-6.6 Millimeter of mercury (mmHg) (±15.26 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-8.6 Millimeter of mercury (mmHg) (±22.25 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-7.2 Millimeter of mercury (mmHg) (±20.70 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-16.0 Millimeter of mercury (mmHg) (±NA Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.5 Millimeter of mercury (mmHg) (±7.78 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-5.3 Millimeter of mercury (mmHg) (±8.54 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-6.9 Millimeter of mercury (mmHg) (±17.09 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-6.3 Millimeter of mercury (mmHg) (±6.24 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.2 Millimeter of mercury (mmHg) (±8.42 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0.8 Millimeter of mercury (mmHg) (±11.62 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-11.3 Millimeter of mercury (mmHg) (±11.24 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-1.6 Millimeter of mercury (mmHg) (±9.53 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.9 Millimeter of mercury (mmHg) (±10.50 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-17.0 Millimeter of mercury (mmHg) (±9.31 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-1.8 Millimeter of mercury (mmHg) (±6.56 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.9 Millimeter of mercury (mmHg) (±17.03 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-8.2 Millimeter of mercury (mmHg) (±18.74 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.1 Millimeter of mercury (mmHg) (±8.15 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.4 Millimeter of mercury (mmHg) (±12.08 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.8 Millimeter of mercury (mmHg) (±24.78 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-6.3 Millimeter of mercury (mmHg) (±10.24 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-8.9 Millimeter of mercury (mmHg) (±11.54 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-6.7 Millimeter of mercury (mmHg) (±11.18 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.3 Millimeter of mercury (mmHg) (±6.40 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-20.0 Millimeter of mercury (mmHg) (±NA Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.8 Millimeter of mercury (mmHg) (±9.83 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.7 Millimeter of mercury (mmHg) (±13.76 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-6.2 Millimeter of mercury (mmHg) (±10.37 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-3.4 Millimeter of mercury (mmHg) (±9.62 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-2.3 Millimeter of mercury (mmHg) (±10.33 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-1.3 Millimeter of mercury (mmHg) (±15.64 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-8.7 Millimeter of mercury (mmHg) (±12.19 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-0.2 Millimeter of mercury (mmHg) (±8.13 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-6.5 Millimeter of mercury (mmHg) (±12.02 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg-16.4 Millimeter of mercury (mmHg) (±10.03 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-9.1 Millimeter of mercury (mmHg) (±13.65 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg13.8 Millimeter of mercury (mmHg) (±19.25 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-4.8 Millimeter of mercury (mmHg) (±11.10 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-4.2 Millimeter of mercury (mmHg) (±12.87 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-4.4 Millimeter of mercury (mmHg) (±15.18 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg7.0 Millimeter of mercury (mmHg) (±20.28 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-5.2 Millimeter of mercury (mmHg) (±13.08 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-2.0 Millimeter of mercury (mmHg) (±5.05 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-4.7 Millimeter of mercury (mmHg) (±6.51 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-10.7 Millimeter of mercury (mmHg) (±11.02 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-8.0 Millimeter of mercury (mmHg) (±19.80 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-19.5 Millimeter of mercury (mmHg) (±6.36 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-34.0 Millimeter of mercury (mmHg) (±NA Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-1.2 Millimeter of mercury (mmHg) (±12.46 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-3.9 Millimeter of mercury (mmHg) (±22.76 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-2.7 Millimeter of mercury (mmHg) (±24.73 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-9.3 Millimeter of mercury (mmHg) (±23.54 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-7.9 Millimeter of mercury (mmHg) (±24.43 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-13.8 Millimeter of mercury (mmHg) (±25.15 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-7.8 Millimeter of mercury (mmHg) (±26.06 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-5.2 Millimeter of mercury (mmHg) (±10.71 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-6.3 Millimeter of mercury (mmHg) (±5.51 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-26.7 Millimeter of mercury (mmHg) (±37.75 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-34.0 Millimeter of mercury (mmHg) (±38.18 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-38.0 Millimeter of mercury (mmHg) (±32.53 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg-84.0 Millimeter of mercury (mmHg) (±NA Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg2.1 Millimeter of mercury (mmHg) (±8.64 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg3.2 Millimeter of mercury (mmHg) (±9.98 Standard Deviation)
NCT00272987Breast NeoplasmsExtent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Mean/Standard Deviation
From the date of the first dose of the investigational product to end of study, up to approx. 14 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg60.7 Weeks (±72.07 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg26.9 Weeks (±16.88 Standard Deviation)
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg70.9 Weeks (±115.44 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg72.2 Weeks (±88.66 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg93.1 Weeks (±147.92 Standard Deviation)
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg29.4 Weeks (±23.00 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg62.3 Weeks (±75.52 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg82.5 Weeks (±135.79 Standard Deviation)
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg23.8 Weeks (±14.87 Standard Deviation)
NCT00272987Breast NeoplasmsExtent of Exposure to Lapatinib, Trastuzumab and Paclitaxel by Median/Min-Max
From the date of the first dose of the investigational product to end of study, up to approx. 14 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg33.0 Weeks
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg33.0 Weeks
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg22.0 Weeks
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg23.5 Weeks
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg37.0 Weeks
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg38.5 Weeks
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg32.5 Weeks
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg22.0 Weeks
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg31.5 Weeks
NCT00272987Breast NeoplasmsNumber of Events of Diarrhea With the Indicated Characteristics
From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Events of diarrhea
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg358 Events of diarrhea
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg347 Events of diarrhea
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Events of diarrhea
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg4 Events of diarrhea
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg75 Events of diarrhea
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg90 Events of diarrhea
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Events of diarrhea
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Events of diarrhea
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Events of diarrhea
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Events of diarrhea
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg26 Events of diarrhea
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Events of diarrhea
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Events of diarrhea
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg37 Events of diarrhea
NCT00272987Breast NeoplasmsNumber of Events of Hepatotoxicity With the Indicated Characteristics
From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Events of hepatotoxicity
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg6 Events of hepatotoxicity
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg5 Events of hepatotoxicity
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Events of hepatotoxicity
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Events of hepatotoxicity
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Events of hepatotoxicity
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Events of hepatotoxicity
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg2 Events of hepatotoxicity
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Events of hepatotoxicity
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Events of hepatotoxicity
NCT00272987Breast NeoplasmsNumber of Events of Rash With the Indicated Characteristics
From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 3.5 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg55 Events of rash
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg69 Events of rash
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Events of rash
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Events of rash
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Events of rash
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Events of rash
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg23 Events of rash
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Events of rash
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg12 Events of rash
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Events of rash
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Events of rash
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Events of rash
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Events of rash
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg20 Events of rash
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg7 Events of rash
NCT00272987Breast NeoplasmsNumber of Participants Who Died Due to Any Cause
From the date of the first dose of investigational product until last patient last visit, up to approximately 14 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg12 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
NCT00272987Breast NeoplasmsNumber of Participants Who Received Any Concomitant Medications During the Study Period
withdrawal/study completion, up to approx. 3.5 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg29 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg14 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg20 Participants
NCT00272987Breast NeoplasmsNumber of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
From the date of the first dose of investigational product until 30 days after the last dose of investigational product, up to approx. 14 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg29 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg14 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg6 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg14 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg5 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg20 Participants
NCT00272987Breast NeoplasmsNumber of Participants With at Least 1 Event of Left Ventricular Ejection Fraction Decrease With the Indicated Characteristics
Baseline and every 8 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg8 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
NCT00272987Breast NeoplasmsNumber of Participants With the Indicated Eastern Cooperative Oncology Group (ECOG) Performance Status Value
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
NCT00272987Breast NeoplasmsNumber of Participants With the Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg6 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg5 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg11 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg5 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg15 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg14 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg7 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg10 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg7 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg5 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg6 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg8 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg9 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg6 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg6 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg6 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg2 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg3 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg5 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg3 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg3 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg6 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg4 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg2 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg2 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg2 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
NCT00272987Breast NeoplasmsNumber of Participants With the Maximum Toxicity Grade for the Indicated Clinical Hematology Parameters
Baseline and every 4 weeks thereafter up to withdrawal/study completion and 30 day follow-up, up to approx. 3.5 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg10 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg5 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg10 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg8 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg7 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg7 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg7 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg19 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg5 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg4 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg2 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg6 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg3 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg4 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg1 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg4 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg11 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg5 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg4 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg2 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg4 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg7 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg7 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg4 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg5 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg0 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg1 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg6 Participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg11 Participants
NCT00272987Breast NeoplasmsOverall Response (OR): Percentage of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Confirmed Partial Response (PR) as Assessed by the Investigator
From the date of the first dose of investigational product to end of study, up to approx. 7 years
Cohort 1: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg79.3 Percentage of participants
Cohort 2: Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg71.4 Percentage of participants
Cohort 3: Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg70.0 Percentage of participants
NCT00281658Breast NeoplasmsOverall Survival (OS) at 53 Months
From date of randomization until date of death from any cause, assessed up to 53 months (Primary OS analysis cut-off date = 18-Jun-2010)
Lapatinib 1500 mg + Paclitaxel27.8 months
Placebo + Paclitaxel20.5 months
NCT00320385Breast NeoplasmsProgression-Free Survival (PFS)
Baseline to disease progression or death due to any cause or 30 days after last dose (up to 216 weeks)
Lapatinib8.1 weeks
Trastuzumab + Lapatinib12.0 weeks
NCT00374322Breast NeoplasmsNumber of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])
From randomization until date of the first occurrence of an objective disease recurrence, a second primary cancer, or death from any cause (assessed up to 6 years; 1 year of treatment, 5 years of follow-up [median of 5.3 years for final analysis])
Lapatinib 1500 mg1 Participants
Lapatinib 1500 mg1318 Participants
Lapatinib 1500 mg252 Participants
Placebo1285 Participants
Placebo1 Participants
Placebo290 Participants
NCT00390455Breast NeoplasmsProgression-free Survival (PFS)
Interval from randomization until disease progression or death, whichever occurs first, assessed up to 5 years
Arm I (Lapatinib)4.7 months
Arm II (Placebo)3.8 months
NCT00424255Head and Neck NeoplasmsDisease Free Survival (DFS)
From randomization until the earliest date of disease recurrence or death due to any cause (average of 101 study weeks)
Lapatinib 1500 mg53.6 Months
PlaceboNA Months
NCT00486954Stomach NeoplasmsNumber of Participants With Dose Limiting Toxicities (DLTs) in the Pilot Part of the Study
28 days
Lapatinib Plus Paclitaxel in Gastrectomy Participants1 Participants
Lapatinib Plus Paclitaxel in Non-gastrectomy Participants2 Participants
NCT00486954Stomach NeoplasmsOverall Survival (OS) in the Randomized Part of the Study
From randomization until death due to any cause (up to 42.58 months)
Lapatinib Plus Paclitaxel11.0 months
Paclitaxel Alone8.9 months
NCT00490139
ALTTO
Breast NeoplasmsDisease-Free Survival (DFS) at the Primary Analysis
From randomization until the date of the first occurrence of disease recurrence, a contralateral invasive breast cancer, a second primary cancer, or death from any cause (median follow-up of 4.5 years)
LapatinibNA Years
LapatinibNA Years
Lapatinib1.0 Years
Lapatinib1.8 Years
Lapatinib2.8 Years
Lapatinib Plus Trastuzumab6.1 Years
Lapatinib Plus Trastuzumab5.1 Years
Lapatinib Plus Trastuzumab6.1 Years
Lapatinib Plus Trastuzumab1.9 Years
Lapatinib Plus Trastuzumab3.2 Years
Trastuzumab5.6 Years
TrastuzumabNA Years
Trastuzumab1.5 Years
Trastuzumab2.6 Years
Trastuzumab4.2 Years
Trastuzumab Followed by Lapatinib2.8 Years
Trastuzumab Followed by LapatinibNA Years
Trastuzumab Followed by LapatinibNA Years
Trastuzumab Followed by Lapatinib4.8 Years
Trastuzumab Followed by Lapatinib1.3 Years
NCT00508274Breast NeoplasmsClinical Benefit Rate (CBR)
Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 90 months
Lapatinib + Capecitabine57.7 Percentage of participants
NCT00553358
Neo ALTTO
Breast NeoplasmsNumber of Participants With Pathological Complete Response (pCR) at the Time of Surgery
Weeks 20 to 22
Lapatinib 1000/750 mg + Trastuzumab 2 mg/kg78 participants
Lapatinib 1500 mg38 participants
Trastuzumab 2 mg/kg44 participants
NCT00667251Breast NeoplasmsProgression Free Survival (PFS) at the Time of Primary Results
From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up to approximately 39 months
Lapatinib (LTax/L)8.97 Months
Lapatinib (LTax/L)9.13 Months
Trastuzumab (TTax/T)13.63 Months
Trastuzumab (TTax/T)11.30 Months
NCT00680901NeoplasmsOverall Survival at the Time of Primary Analysis
From date of randomization till death due to any cause, assessed up the cut-off date for Primary Analysis (24-Sep-2012) (average of 4 years)
CapeOx Plus Lapatinib12.2 Months
CapeOx Plus Placebo10.5 Months
NCT00680901NeoplasmsOverall Survival in All Randomized Participants at the Time of Primary Analysis
From date of randomization till death due to any cause, assessed up the cut-off date for Primary Analysis (24-Sep-2012) (average of 4 years)
CapeOx Plus Lapatinib11.9 Months
CapeOx Plus Placebo10.4 Months
NCT00770809Breast NeoplasmspCR Rate
At time of surgery
Arm I (THL)56 percentage of participants
Arm II (TH)46 percentage of participants
Arm III (TL)32 percentage of participants
NCT00820222Breast NeoplasmsNumber of Participants With Central Nervous System (CNS) Metastases (as Assessed by Independent Review) as the Site of First Relapse
From randomization until disease progression, death, or discontinuation from the study (average of 10 months). Cut-off 11-Jun-2012
Lapatinib Plus Capecitabine8 participants
Trastuzumab Plus Capecitabine12 participants
NCT00829166
EMILIA
Breast NeoplasmsOverall Survival: Final Analysis
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Lapatinib + Capecitabine25.9 Months
Trastuzumab Emtansine29.9 Months
NCT00829166
EMILIA
Breast NeoplasmsOverall Survival: Second Interim Analysis (Co-primary Endpoint)
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Lapatinib + Capecitabine25.1 Months
Trastuzumab Emtansine30.9 Months
NCT00829166
EMILIA
Breast NeoplasmsPercentage of Participants Who Died: Final Analysis
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Lapatinib + Capecitabine67.1 percentage of participants
Trastuzumab Emtansine61.2 percentage of participants
NCT00829166
EMILIA
Breast NeoplasmsPercentage of Participants Who Died: Second Interim Analysis
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Lapatinib + Capecitabine36.7 percentage of participants
Trastuzumab Emtansine30.1 percentage of participants
NCT00829166
EMILIA
Breast NeoplasmsPercentage of Participants Who Were Alive at Year 1
Year 1
Lapatinib + Capecitabine78.9 percentage of participants
Trastuzumab Emtansine85.3 percentage of participants
NCT00829166
EMILIA
Breast NeoplasmsPercentage of Participants Who Were Alive at Year 2
Year 2
Lapatinib + Capecitabine52.4 percentage of participants
Trastuzumab Emtansine59.6 percentage of participants
NCT00829166
EMILIA
Breast NeoplasmsPercentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Lapatinib + Capecitabine61.3 percentage of participants
Trastuzumab Emtansine53.5 percentage of participants
NCT00829166
EMILIA
Breast NeoplasmsProgression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Lapatinib + Capecitabine6.4 Months
Trastuzumab Emtansine9.6 Months
NCT00968968NeoplasmsProgression-free Survival
Time from randomization until disease progression or death, approximately 4 years
Lapatinib + Trastuzumab25 months
Trastuzumab2 months
NCT01160211Breast NeoplasmsMedian Kaplan Meier Estimates for PFS in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)
From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 5 years
Lapatinib + Trastuzumab + Aromatase Inhibitor (AI)11.0 Months
Trastuzumab + Aromatase Inhibitor (AI)5.6 Months
NCT01160211Breast NeoplasmsProgression Free Survival (PFS) Events in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI)
From date of randomization until date of progression or date of death from any cause, whichever comes first, assessed up approximately 5 years
Lapatinib + Trastuzumab + Aromatase Inhibitor (AI)7 Participants
Lapatinib + Trastuzumab + Aromatase Inhibitor (AI)51 Participants
Lapatinib + Trastuzumab + Aromatase Inhibitor (AI)62 Participants
Trastuzumab + Aromatase Inhibitor (AI)3 Participants
Trastuzumab + Aromatase Inhibitor (AI)75 Participants
Trastuzumab + Aromatase Inhibitor (AI)39 Participants
NCT01512745Stomach NeoplasmsOverall Survival(OS)
30 months
Apatinib6.5 month
Placebo4.7 month
NCT01512745Stomach NeoplasmsProgression Free Survival(PFS)
30 months
Apatinib2.6 month
Placebo1.8 month
NCT01808573
NALA
—Centrally Assessed Progression Free Survival
From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.
Lapatinib Plus Capecitabine6.6 months
Neratinib Plus Capecitabine8.8 months
NCT01808573
NALA
—Overall Survival
From randomization date to death, assessed up to 59 months.The result is based on primary analysis data cut.
Lapatinib Plus Capecitabine22.2 months
Neratinib Plus Capecitabine24.0 months
NCT02329860Carcinoma, HepatocellularOverall Survival
Approximately 36 months
Apatinib8.7 months
Placebo6.8 months
NCT03523585Breast NeoplasmsProgression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine
Baseline up to 46 months postdose
Trastuzumab Deruxtecan (T-DXd)17.8 months
Treatment of Investigator's/Physician's Choice (TPC)6.9 months
NCT03764293Neoplasm MetastasisOverall Survival (OS)
Up to approximately 3 years
Camrelizumab+Rivoceranib Arm22.1 months
Sorafenib Arm15.2 months
NCT03764293Neoplasm MetastasisProgression-free Survival (PFS) Evaluated by the Blinded Independent Review Committee (BIRC) Based on RECIST v1.1
Up to approximately 3 years
Camrelizumab+Rivoceranib Arm5.6 months
Sorafenib Arm3.7 months

Publications by year

1969–2026: 690 publications.

1969
1
1973
1
1983
1
1987
1
1988
1
1991
3
1992
1
1994
4
1995
1
1996
3
1997
1
1998
8
1999
2
2000
6
2001
15
2002
13
2003
13
2004
11
2005
16
2006
9
2007
10
2008
12
2009
18
2010
25
2011
25
2012
31
2013
27
2014
44
2015
42
2016
36
2017
29
2018
21
2019
28
2020
42
2021
47
2022
57
2023
32
2024
25
2025
18
2026
10

Publications by indication

Breast Neoplasms (236)

  • The role of the molecular tumor board: learnings from the ROME trial.
    NPJ Precis Oncol · 2026 · PMID 41963505 · NCT04591431
  • A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer.
    Front Oncol · 2026 · PMID 33659204 · NCT03535961
  • Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial.
    Signal Transduct Target Ther · 2025 · PMID 39915443 · NCT04722718
  • Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.
    Nat Med · 2025 · PMID 41023484 · NCT04591431
  • Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.
    Cell Rep Med · 2025 · PMID 40480221 · NCT00770809

Stomach Neoplasms (57)

  • Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
    BMJ · 2026 · PMID 41819560 · NCT03813784
  • DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer.
    J Gastrointest Oncol · 2026 · PMID 41816563 · NCT06385873
  • Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma.
    J Natl Compr Canc Netw · 2025 · PMID 40341124 · NCT06346392
  • PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.
    Signal Transduct Target Ther · 2025 · PMID 40082418 · NCT04609176
  • Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
    Lancet · 2025 · PMID 40460847 · NCT04581473

Neoplasm Metastasis (39)

  • Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
    Lancet Oncol · 2025 · PMID 41308676 · NCT03764293
  • Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort.
    Cancers (Basel) · 2023 · PMID 37444551 · NCT02029001
  • Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
    Lancet · 2023 · PMID 37499670 · NCT03764293
  • Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
    BMC Med · 2023 · PMID 37147645 · NCT02426034
  • Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial.
    BMC Cancer · 2022 · PMID 34740331 · NCT03784014

Carcinoma, Hepatocellular (36)

  • Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.
    J Clin Oncol · 2026 · PMID 41734362 · NCT04559607
  • Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
    Lancet · 2025 · PMID 41125112 · NCT04521153
  • Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma.
    Clin Mol Hepatol · 2025 · PMID 39300923 · NCT07314372
  • Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
    Lancet · 2025 · PMID 39798578 · NCT07157969
  • Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
    J Hepatocell Carcinoma · 2024 · PMID 36578526 · NCT05717738

Lung Neoplasms (26)

  • Primary lymphoepithelioma-like carcinoma of the lung: An unusual cancer and clinical outcomes of 14 patients.
    Oncol Lett · 2024 · PMID 28928848 · NCT03709953
  • Salvage treatment with apatinib for advanced non-small-cell lung cancer.
    Onco Targets Ther · 2022 · PMID 28367065 · NCT03709953
  • Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome.
    J Thorac Dis · 2020 · PMID 28203414 · NCT03709953
  • Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature.
    Transl Lung Cancer Res · 2020 · PMID 28149767 · NCT03709953
  • Lymphoepithelioma-Like Carcinoma of the Esophagus: A Rare Tumor.
    J Coll Physicians Surg Pak · 2018 · PMID 28969745 · NCT03709953

Colorectal Neoplasms (22)

  • Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study.
    Front Oncol · 2022 · PMID 34540697 · NCT03397199
  • Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study.
    Ann Transl Med · 2022 · PMID 35282086 · NCT03210064
  • Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.
    ESMO Open · 2021 · PMID 32988996 · NCT03225937
  • Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Lancet Oncol · 2017 · PMID 27108243 · NCT03225937
  • Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
    Clin Cancer Res · 2016 · PMID 26341920 · NCT02829385

Publications by journal

Trial-results highlights

In a study of HER2-positive advanced or metastatic breast cancer (NCT00073528), the number of participants with progression-free survival (PFS) was evaluated. In the arm receiving Lapatinib 1500 mg + Letrozole 2.5 mg, there were 88 participants. In the arm receiving Placebo + Letrozole 2.5 mg, there were 89 participants. The median PFS in the Lapatinib 1500 mg + Letrozole 2.5 mg arm was 35.4 weeks, while the median PFS in the Placebo + Letrozole 2.5 mg arm was 13.0 weeks.

Another study (NCT00075270) investigated time to progression in breast neoplasms. When evaluated by an Independent Review Committee, the median time to progression was 33.7 weeks for the Lapatinib With Paclitaxel arm and 26.1 weeks for the Placebo With Paclitaxel arm. When evaluated by the investigator, the median time to progression was 29.0 weeks for the Lapatinib With Paclitaxel arm and 22.9 weeks for the Placebo With Paclitaxel arm.

A separate study (NCT00272987) explored various physiological changes and exposure to Lapatinib in combination with paclitaxel and trastuzumab in breast neoplasms. In Cohort 1 (Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg), mean changes from baseline in body temperature were -0.100, 0.011, 0.021, -0.052, 0.018, and 0.157 Degree Celsius. Mean changes from baseline in heart rate were -4.667, 0.800, -0.500, -0.714, -8.286, and -4.667 Beats per minute (BPM). Mean changes from baseline in systolic and diastolic blood pressure were -2.0, 3.2, 1.6, 7.1, -7.7, and -14.5 Millimeter of mercury (mmHg). The mean extent of exposure to the combination therapy was also reported:

  • For Cohort 1 (Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 1000 mg), mean exposure durations were 60.7 weeks, 26.9 weeks, and 70.9 weeks.
  • For Cohort 2 (Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg), mean exposure durations were 72.2 weeks, 93.1 weeks, and 29.4 weeks.
All values reported are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Apatinib publications (690)

2026 (10 papers)

  1. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial.
    Zhu HD, Fan WJ, Zhao C, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41734362 · NCT04559607 · Carcinoma, Hepatocellular
  2. Real-world study of SHR-1210 plus apatinib in the treatment of BRAF-negative mucosal melanoma: efficacy, safety and implications of precision medicine.
    Zhang Y, Wang T, Lyu AQ, et al. · Front Immunol · 2026 · Derived
    PubMed: PMID 42093981 · NCT03986515
  3. Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial.
    Zhang X, Sun D, Zhang Y, et al. · BMC Med · 2026 · Derived
    PubMed: PMID 41408254 · NCT04560127
  4. Neoadjuvant mFOLFOX6 plus camrelizumab and apatinib in colon cancer and biomarker research via spatiotemporal-omics profiling.
    Tong Z, Gao L, Wang D, et al. · NPJ Precis Oncol · 2026 · Derived
    PubMed: PMID 41922688 · NCT04625803 · Colonic Neoplasms
  5. Camrelizumab Plus Apatinib in Advanced Unresectable Alveolar Soft Part Sarcoma and Undifferentiated Pleomorphic Sarcoma Patients: A Single-Center, Exploratory Case Series.
    Tan H, Wang H, Zhou J, et al. · Ther Clin Risk Manag · 2026 · Derived
    PubMed: PMID 42051923 · NCT04447274 · Sarcoma
  6. Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
    Peng Z, Zhang Y, Xu H, et al. · BMJ · 2026 · Derived
    PubMed: PMID 41819560 · NCT03813784 · Stomach Neoplasms
  7. The role of the molecular tumor board: learnings from the ROME trial.
    Marchetti P, Curigliano G, Westphalen CB, et al. · NPJ Precis Oncol · 2026 · Derived
    PubMed: PMID 41963505 · NCT04591431 (ROME) · Breast Neoplasms
  8. A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer.
    Hu N, Zhu A, Si Y, et al. · Front Oncol · 2026 · Derived
    PubMed: PMID 33659204 · NCT03535961 · Breast Neoplasms
  9. DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer.
    Ding Y, Qian H, Liu H, et al. · J Gastrointest Oncol · 2026 · Derived
    PubMed: PMID 41816563 · NCT06385873 · Stomach Neoplasms
  10. A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer.
    Cao CD, McCorkle JR, Yan D, et al. · Cancers (Basel) · 2026 · Derived
    PubMed: PMID 41749879 · NCT04608409 · Ovarian Neoplasms

2025 (18 papers)

  1. Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).
    Li C, Tian Y, Zheng Y, et al. · J Clin Oncol · 2025 · Trial result
    PubMed: PMID 39383487 · NCT07026149 · Adenocarcinoma
  2. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma.
    Yu J, Mehta R · J Natl Compr Canc Netw · 2025 · Derived
    PubMed: PMID 40341124 · NCT06346392 · Stomach Neoplasms
  3. LRRC25 Is a Potential Biomarker for Predicting Immunotherapy Response in Patients with Gastric Cancer.
    Yang Z, Yu B, Hu J, et al. · Dig Dis Sci · 2025 · Derived
    PubMed: PMID 39961962 · NCT04208347 · Adenocarcinoma
  4. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
    Wang Z, Fan J, Zhou S, et al. · Lancet · 2025 · Derived
    PubMed: PMID 41125112 · NCT04521153 · Carcinoma, Hepatocellular
  5. PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.
    Wang Y, Lu J, Chong X, et al. · Signal Transduct Target Ther · 2025 · Derived
    PubMed: PMID 40082418 · NCT04609176 · Stomach Neoplasms
  6. The Prognostication of Surgically Resected Head and Neck Squamous Cell Carcinoma Using Pre-Therapy Neutrophil and Lymphocyte Counts.
    Sunkara PR, Chow E, Waitzman J, et al. · Head Neck · 2025 · Derived
    PubMed: PMID 39415507 · NCT00424255 · Head and Neck Neoplasms
  7. BRAFV600E mutation is associated with better prognoses in radioactive iodine refractory thyroid cancer patients treated with multi-kinase inhibitors: a retrospective analysis of registered clinical trials.
    Sun D, Zhang X, Jin X, et al. · Thyroid Res · 2025 · Derived
    PubMed: PMID 39924483 · NCT02731352 · Thyroid Neoplasms
  8. Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial.
    Shen G, Liu Z, Wang M, et al. · Signal Transduct Target Ther · 2025 · Derived
    PubMed: PMID 39915443 · NCT04722718 · Breast Neoplasms
  9. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
    Qin S, Gu S, Chan SL, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 41308676 · NCT03764293 · Neoplasm Metastasis
  10. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
    Qi C, Liu C, Peng Z, et al. · Lancet · 2025 · Derived
    PubMed: PMID 40460847 · NCT04581473 · Stomach Neoplasms
  11. Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.
    Marchetti P, Curigliano G, Biffoni M, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41023484 · NCT04591431 (ROME) · Breast Neoplasms
  12. Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial.
    Liu M, Qiu G, Guan W, et al. · Signal Transduct Target Ther · 2025 · Derived
    PubMed: PMID 39962074 · NCT05001412
  13. Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.
    Li H, Liu J, Ouyang Q, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 41308673 · NCT04296370
  14. Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.
    Jaehnig EJ, Fernandez-Martinez A, Vashist TD, et al. · Cell Rep Med · 2025 · Derived
    PubMed: PMID 40480221 · NCT00770809 · Breast Neoplasms
  15. Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study.
    Guo Z, Liu J, Zhang X, et al. · Endocrine · 2025 · Derived
    PubMed: PMID 40304938 · NCT06482086
  16. TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis.
    Crown J, Eustace AJ, Collins DM, et al. · Acta Oncol · 2025 · Derived
    PubMed: PMID 40468999 · NCT01485926 (TCHL Phase II) · Breast Neoplasms
  17. Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma.
    Li B, Wen J, Xu Z, et al. · Clin Mol Hepatol · 2025 · Background
    PubMed: PMID 39300923 · NCT07314372 (FAD-HCC-001) · Carcinoma, Hepatocellular
  18. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
    Kudo M, Ren Z, Guo Y, et al. · Lancet · 2025 · Background
    PubMed: PMID 39798578 · NCT07157969 · Carcinoma, Hepatocellular

2024 (25 papers)

  1. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Fehm T, Cottone F, Dunton K, et al. · Lancet Oncol · 2024 · Trial result
    PubMed: PMID 38697155 · NCT03523585 · Breast Neoplasms
  2. Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial.
    Zuo WJ, Chen L, Shen Y, et al. · Ther Adv Med Oncol · 2024 · Derived
    PubMed: PMID 38362377 · NCT05582499 (FASCINATE-N) · Breast Neoplasms
  3. A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer.
    Zhang P, Wang L, Zhen Y, et al. · Chin J Cancer Res · 2024 · Derived
    PubMed: PMID 38455366 · NCT06313983 · Breast Neoplasms
  4. Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial.
    Yu W, Zhang H, Chen J, et al. · Ann Transl Med · 2024 · Derived
    PubMed: PMID 36267741 · NCT03064243 · Sarcoma
  5. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors.
    Xu G, Liu W, Wang Y, et al. · Cell Rep Med · 2024 · Derived
    PubMed: PMID 39232496 · NCT06346392 · Stomach Neoplasms
  6. Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study.
    Wei Q, Xu X, Li J, et al. · Oncologist · 2024 · Derived
    PubMed: PMID 38366886 · NCT04190745
  7. Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy.
    Wang X, Li W, Yin Y, et al. · Transl Breast Cancer Res · 2024 · Derived
    PubMed: PMID 38751488 · NCT03084939 · Breast Neoplasms
  8. Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study.
    Wang C, Huang M, Geng Q, et al. · Ther Adv Med Oncol · 2024 · Derived
    PubMed: PMID 34484431 · NCT03427242 · Biliary Tract Neoplasms
  9. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
    Rediti M, Venet D, Joaquin Garcia A, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 39613746 · NCT00490139 (ALTTO) · Breast Neoplasms
  10. Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials.
    Qi C, Zhang P, Liu C, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38788174 · NCT04581473 · Stomach Neoplasms
  11. Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study.
    Pu X, Lin G, Xiao M, et al. · EClinicalMedicine · 2024 · Derived
    PubMed: PMID 38261958 · NCT04459078 · Adenocarcinoma of Lung
  12. Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.
    Mo Y, Pan Y, Zhang B, et al. · Front Immunol · 2024 · Derived
    PubMed: PMID 38239359 · NCT04350190 · Nasopharyngeal Carcinoma
  13. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.
    Lin JX, Tang YH, Zheng HL, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 38167806 · NCT04195828
  14. Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors.
    Kang YK, Ryu MH, Hong YS, et al. · Cancer Res Treat · 2024 · Derived
    PubMed: PMID 38271925 · NCT02711969 · Stomach Neoplasms
  15. Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study.
    Jing C, Bai Z, Tong K, et al. · Oncologist · 2024 · Derived
    PubMed: PMID 39102756 · NCT04720131 · Biliary Tract Neoplasms
  16. PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study.
    Gou M, Zhang Y, Wang Z, et al. · Invest New Drugs · 2024 · Derived
    PubMed: PMID 38347177 · NCT04182724
  17. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
    Fehm T, Mueller V, Banys-Paluchowski M, et al. · Clin Chem · 2024 · Derived
    PubMed: PMID 38175595 · NCT01619111 (DETECT III) · Breast Neoplasms
  18. Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial.
    Zhu YC, Wei ZG, Wang JJ, et al. · Nat Commun · 2024 · Background
    PubMed: PMID 39609453 · NCT06831175 · Adrenal Gland Neoplasms
  19. Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?
    Salati M, Di Emidio K, Tarantino V, et al. · ESMO Open · 2024 · Background
    PubMed: PMID 29209523 · NCT05029453 · Stomach Neoplasms
  20. Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
    Luo L, He Y, Zhu G, et al. · J Hepatocell Carcinoma · 2024 · Background
    PubMed: PMID 36578526 · NCT05717738 (CCGLC-008) · Carcinoma, Hepatocellular
  21. Primary lymphoepithelioma-like carcinoma of the lung: An unusual cancer and clinical outcomes of 14 patients.
    Lin L, Lin T, Zeng B, et al. · Oncol Lett · 2024 · Background
    PubMed: PMID 28928848 · NCT03709953 (Spark-AL003) · Lung Neoplasms
  22. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.
    Lin J, Yang X, Long J, et al. · Hepatobiliary Surg Nutr · 2024 · Background
    PubMed: PMID 32832493 · NCT04720131 · Biliary Tract Neoplasms
  23. Multiomics identifies metabolic subtypes based on fatty acid degradation allocating personalized treatment in hepatocellular carcinoma.
    Li B, Li Y, Zhou H, et al. · Hepatology · 2024 · Background
    PubMed: PMID 37540187 · NCT07314372 (FAD-HCC-001) · Carcinoma, Hepatocellular
  24. Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-arm trial.
    Jiang W, Li R, Zhang L, et al. · Front Oncol · 2024 · Background
    PubMed: PMID 37251944 · NCT03267121 · Head and Neck Neoplasms
  25. Cholangiocarcinoma - evolving concepts and therapeutic strategies.
    Ilyas SI, Khan SA, Hallemeier CL, et al. · Nat Rev Clin Oncol · 2024 · Background
    PubMed: PMID 28994423 · NCT04720131 · Biliary Tract Neoplasms

2023 (32 papers)

  1. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
    Blay JY, Chevret S, Le Cesne A, et al. · Lancet Oncol · 2023 · Trial result
    PubMed: PMID 37429302 · NCT06140732 · Chordoma
  2. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    André F, Hee Park Y, Kim SB, et al. · Lancet · 2023 · Trial result
    PubMed: PMID 37086745 · NCT03523585 · Breast Neoplasms
  3. A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas.
    Zhou Y, Li M, Zhang B, et al. · BMC Med · 2023 · Derived
    PubMed: PMID 38031088 · NCT04074564 · Sarcoma
  4. Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis.
    Zhou X, Cao J, Topatana W, et al. · Immunotherapy · 2023 · Derived
    PubMed: PMID 36852452 · NCT03463876 · Carcinoma, Hepatocellular
  5. Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.
    Zhang L, Wang W, Ge S, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36872337 · NCT05025033 · Stomach Neoplasms
  6. Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial.
    Yuan L, Jia GD, Lv XF, et al. · Nat Commun · 2023 · Derived
    PubMed: PMID 37580352 · NCT04548271 · Nasopharyngeal Carcinoma
  7. Combined all-trans retinoic acid with low-dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single-center, secondary analysis of a phase II study.
    Ye L, Zhang L, Li R, et al. · Cancer Med · 2023 · Derived
    PubMed: PMID 36734294 · NCT02775370 · Carcinoma, Adenoid Cystic
  8. Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer.
    Yan C, Huang H, Zheng Z, et al. · Front Immunol · 2023 · Derived
    PubMed: PMID 37275884 · NCT03671265 · Esophageal Neoplasms
  9. Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial.
    Wong SJ, Torres-Saavedra PA, Saba NF, et al. · JAMA Oncol · 2023 · Derived
    PubMed: PMID 37768670 · NCT01711658 (TRYHARD) · Head and Neck Neoplasms
  10. Multiparametric immune profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: an exploratory study of the CLAP trial.
    Wang Y, Lai Y, Peng H, et al. · Clin Transl Oncol · 2023 · Derived
    PubMed: PMID 36115931 · NCT03816553 · Uterine Cervical Neoplasms
  11. Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial.
    Wang X, Wu X, Yang Y, et al. · Eur J Cancer · 2023 · Derived
    PubMed: PMID 36753834 · NCT03955354 · Melanoma
  12. Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort.
    Trédan O, Toulmonde M, Le Tourneau C, et al. · Cancers (Basel) · 2023 · Derived
    PubMed: PMID 37444551 · NCT02029001 (MOST plus) · Neoplasm Metastasis
  13. Association of Surgical Margin Distance With Survival in Patients With Resected Head and Neck Squamous Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial.
    Sunkara PR, Graff JT, Cramer JD, et al. · JAMA Otolaryngol Head Neck Surg · 2023 · Derived
    PubMed: PMID 36821132 · NCT00424255 · Head and Neck Neoplasms
  14. Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors.
    Shen J, Yan J, Du J, et al. · Front Immunol · 2023 · Derived
    PubMed: PMID 37056765 · NCT04569916
  15. Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
    Rastogi P, Tang G, Hassan S, et al. · Breast Cancer Res Treat · 2023 · Derived
    PubMed: PMID 36944848 · NCT00486668
  16. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
    Qin S, Chan SL, Gu S, et al. · Lancet · 2023 · Derived
    PubMed: PMID 37499670 · NCT03764293 · Neoplasm Metastasis
  17. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer.
    Qi C, Xie T, Zhou J, et al. · J Hematol Oncol · 2023 · Derived
    PubMed: PMID 37689733 · NCT04581473 · Stomach Neoplasms
  18. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
    Newhouse R, Nelissen E, El-Shakankery KH, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37407274 · NCT04348032 (APPROVE)
  19. Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.
    Mao L, Lian B, Li C, et al. · JAMA Oncol · 2023 · Derived
    PubMed: PMID 37261804 · NCT04397770 · Melanoma
  20. Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
    Ma Y, Chen Q, Zhang Y, et al. · Cancer Chemother Pharmacol · 2023 · Derived
    PubMed: PMID 37518060 · NCT04390984
  21. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
    Liu Y, Wang W, Yin R, et al. · BMC Med · 2023 · Derived
    PubMed: PMID 37775744 · NCT03075462 · Ovarian Neoplasms
  22. Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.
    Liu J, He M, Ou K, et al. · Int J Cancer · 2023 · Derived
    PubMed: PMID 37676110 · NCT03735082 · Breast Neoplasms
  23. Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
    Li J, Qin S, Wen L, et al. · BMC Med · 2023 · Derived
    PubMed: PMID 37147645 · NCT02426034 · Neoplasm Metastasis
  24. Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial.
    Hou Z, Lan C, Huang X, et al. · Transl Cancer Res · 2023 · Derived
    PubMed: PMID 37969395 · NCT04383977 · Ovarian Neoplasms
  25. A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE).
    Gumbleton M, Allan S, Conway H, et al. · BMC Res Notes · 2023 · Derived
    PubMed: PMID 36797744 · NCT03407976 (APPEASE) · Adenocarcinoma
  26. Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
    Gaynor N, Blanco A, Madden SF, et al. · Br J Cancer · 2023 · Derived
    PubMed: PMID 37507543 · NCT01485926 (TCHL Phase II) · Breast Neoplasms
  27. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
    Gaitskell K, Rogozińska E, Platt S, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37185961 · NCT03262545
  28. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
    Ding X, Zhang WJ, You R, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36735896 · NCT04586088 · Nasopharyngeal Carcinoma
  29. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials.
    Chumsri S, Li Z, Serie DJ, et al. · NPJ Breast Cancer · 2023 · Derived
    PubMed: PMID 35610260 · NCT00553358 (Neo ALTTO) · Breast Neoplasms
  30. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial.
    Zhu Y, Wen J, Li Q, et al. · Lancet Oncol · 2023 · Background
    PubMed: PMID 36990609 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  31. Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol.
    Huang JT, Zhong JH, Zhang J, et al. · BMJ Open · 2023 · Background
    PubMed: PMID 37770273 · NCT05062837 · Carcinoma, Hepatocellular
  32. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial.
    Chiang CL, Chiu KWH, Chan KSK, et al. · Lancet Gastroenterol Hepatol · 2023 · Background
    PubMed: PMID 36529152 · NCT05717738 (CCGLC-008) · Carcinoma, Hepatocellular

2022 (57 papers)

  1. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.
    Xu J, Shen J, Gu S, et al. · Clin Cancer Res · 2022 · Trial result
    PubMed: PMID 33087333 · NCT04642664 (ACABC) · Cholangiocarcinoma
  2. Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study.
    Xie L, Xu J, Sun X, et al. · Cancer Manag Res · 2022 · Trial result
    PubMed: PMID 32547189 · NCT04260113 (AIAC) · Drug-Related Side Effects and Adverse Reactions
  3. Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial.
    Italiano A, Dinart D, Soubeyran I, et al. · BMC Cancer · 2022 · Trial result
    PubMed: PMID 34740331 · NCT03784014 (MULTISARC) · Neoplasm Metastasis
  4. Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study.
    Hu Y, Lin H, Hao M, et al. · Cancer Manag Res · 2022 · Trial result
    PubMed: PMID 32753952 · NCT04642664 (ACABC) · Cholangiocarcinoma
  5. Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report.
    Deng L, Wang Y, Lu W, et al. · Onco Targets Ther · 2022 · Trial result
    PubMed: PMID 28352185 · NCT03587129 · Ovarian Neoplasms
  6. Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis.
    Zhu Y, Liu K, Wang K, et al. · Front Endocrinol (Lausanne) · 2022 · Derived
    PubMed: PMID 35909569 · NCT03048877
  7. Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study.
    Zhu G, Zhang L, Dou S, et al. · Ther Adv Med Oncol · 2022 · Derived
    PubMed: PMID 33995600 · NCT02775370 · Carcinoma, Adenoid Cystic
  8. Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy.
    Zhou L, Yang Y, Si L, et al. · Melanoma Res · 2022 · Derived
    PubMed: PMID 35190519 · NCT03422445
  9. Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
    Zhou C, Wang Y, Zhao J, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 33323401 · NCT04203485
  10. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
    Zheng Y, Wang Z, Yan C, et al. · Ann Transl Med · 2022 · Derived
    PubMed: PMID 33490196 · NCT04208347 · Adenocarcinoma
  11. Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study.
    Zhao S, Fan N, Li H, et al. · Ann Transl Med · 2022 · Derived
    PubMed: PMID 33178765 · NCT02697838 · Stomach Neoplasms
  12. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
    Zhang Q, Shao B, Tong Z, et al. · BMC Med · 2022 · Derived
    PubMed: PMID 36184642 · NCT03945604 · Triple Negative Breast Neoplasms
  13. Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma.
    Yuan S, Fu Q, Zhao L, et al. · Oncologist · 2022 · Derived
    PubMed: PMID 35348754 · NCT03383237 · Melanoma
  14. Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial.
    Yang C, Zhang J, Zhang Y, et al. · Ther Adv Med Oncol · 2022 · Derived
    PubMed: PMID 35983024 · NCT03243838 (LANCET) · Triple Negative Breast Neoplasms
  15. Efficacy and safety of intermittent versus continuous dose apatinib plus docetaxel as second-line therapy in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma: a randomized controlled study.
    Yan Y, Li H, Wu S, et al. · Ann Transl Med · 2022 · Derived
    PubMed: PMID 35280426 · NCT03334591
  16. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.
    Xing P, Wang M, Zhao J, et al. · Thorac Cancer · 2022 · Derived
    PubMed: PMID 34409776 · NCT04670913 · Parkinson Disease 4, Autosomal Dominant Lewy Body
  17. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
    Xia Y, Tang W, Qian X, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35379737 · NCT04297202 (HCC-009) · Carcinoma, Hepatocellular
  18. Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma.
    Wang Y, Wang C, Zhang Y, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 36330490 · NCT02764268 · Stomach Neoplasms
  19. Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer: The APPROVE Randomized Clinical Trial.
    Wang T, Tang J, Yang H, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 35771546 · NCT04348032 (APPROVE)
  20. The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study.
    Wang D, Yang X, Long J, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 33912461 · NCT04642664 (ACABC) · Cholangiocarcinoma
  21. Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial.
    Tang Z, Wang Y, Yu Y, et al. · BMC Med · 2022 · Derived
    PubMed: PMID 35382819 · NCT03229096 · Stomach Neoplasms
  22. Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial.
    Sun HC, Zhu XD, Zhou J, et al. · Ann Transl Med · 2022 · Derived
    PubMed: PMID 33209881 · NCT03261791 · Carcinoma, Hepatocellular
  23. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
    Subbiah V, Dumbrava EI, Jiang Y, et al. · Exp Hematol Oncol · 2022 · Derived
    PubMed: PMID 32337094 · NCT00543504
  24. An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.
    Stringer-Reasor EM, May JE, Olariu E, et al. · Breast Cancer Res · 2022 · Derived
    PubMed: PMID 33663560 · NCT02158507 · Triple Negative Breast Neoplasms
  25. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
    Shi L, You Q, Wang J, et al. · Endocrine · 2022 · Derived
    PubMed: PMID 35767182 · NCT04180007 (APT-01) · Neoplasm Metastasis
  26. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
    Ruan X, Liang JH, Pan Y, et al. · Cancer · 2022 · Derived
    PubMed: PMID 34043812 · NCT03130270 · Nasopharyngeal Carcinoma
  27. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
    Pizzamiglio S, Cosentino G, Ciniselli CM, et al. · Cancer Med · 2022 · Derived
    PubMed: PMID 34921525 · NCT00553358 (Neo ALTTO) · Breast Neoplasms
  28. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Peng Z, Wei J, Wang F, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 33766817 · NCT03472365 · Stomach Neoplasms
  29. A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
    O'Shea J, Cremona M, Morgan C, et al. · Oncotarget · 2022 · Derived
    PubMed: PMID 29156708 · NCT00524303 · Breast Neoplasms
  30. Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
    Nader-Marta G, Debien V, Eiger D, et al. · Br J Cancer · 2022 · Derived
    PubMed: PMID 36050448 · NCT00490139 (ALTTO) · Breast Neoplasms
  31. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
    Meng X, Wu T, Hong Y, et al. · Lancet Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 34998471 · NCT03736863 · Esophageal Neoplasms
  32. Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade.
    Ma X, Guo Z, Wei X, et al. · Front Immunol · 2022 · Derived
    PubMed: PMID 35046943 · NCT03671265 · Esophageal Neoplasms
  33. Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.
    Liu J, Wang Y, Tian Z, et al. · Nat Commun · 2022 · Derived
    PubMed: PMID 35641481 · NCT04303741 · Breast Neoplasms
  34. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.
    Lin Y, Qin S, Li Z, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 34913959 · NCT03048877
  35. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial.
    Lin JX, Xu YC, Lin W, et al. · JAMA Netw Open · 2022 · Derived
    PubMed: PMID 34241629 · NCT03192735
  36. Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study.
    Li N, Deng W, Zhang G, et al. · Front Oncol · 2022 · Derived
    PubMed: PMID 34540697 · NCT03397199 · Colorectal Neoplasms
  37. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
    Li D, Xu L, Ji J, et al. · Front Immunol · 2022 · Derived
    PubMed: PMID 36091003 · NCT04411706 · Carcinoma, Hepatocellular
  38. A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.
    Ju WT, Xia RH, Zhu DW, et al. · Nat Commun · 2022 · Derived
    PubMed: PMID 36104359 · NCT04393506 · Mouth Neoplasms
  39. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
    Jing C, Wang J, Zhu M, et al. · Cancer Immunol Immunother · 2022 · Derived
    PubMed: PMID 35304622 · NCT04345783 · Stomach Neoplasms
  40. Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
    Jing C, Bai Z, Zhang J, et al. · J Gastrointest Oncol · 2022 · Derived
    PubMed: PMID 34790371 · NCT04338438 · Stomach Neoplasms
  41. Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09).
    Hurvitz S, Singh R, Adams B, et al. · Ther Adv Med Oncol · 2022 · Derived
    PubMed: PMID 30542377 · NCT01783756 · Breast Neoplasms
  42. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
    Huang X, He M, Peng H, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34011535 · NCT03816553 · Uterine Cervical Neoplasms
  43. Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial.
    Hou Z, Zhu K, Yang X, et al. · Ann Transl Med · 2022 · Derived
    PubMed: PMID 33145266 · NCT03046979 (HCC) · Carcinoma, Hepatocellular
  44. Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration.
    Gao G, Ni J, Wang Y, et al. · Transl Lung Cancer Res · 2022 · Derived
    PubMed: PMID 35832447 · NCT03083041 · Carcinoma, Non-Small-Cell Lung
  45. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
    Fumagalli D, Venet D, Ignatiadis M, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 27684533 · NCT00553358 (Neo ALTTO) · Breast Neoplasms
  46. The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005).
    Duan F, Zhong M, Ma Y, et al. · BMC Cancer · 2022 · Derived
    PubMed: PMID 35291977 · NCT02362958
  47. CHST7 Methylation Status Related to the Proliferation and Differentiation of Pituitary Adenomas.
    Dong W, Shi W, Liu Y, et al. · Cells · 2022 · Derived
    PubMed: PMID 35954244 · NCT00939523 · Pituitary Neoplasms
  48. Apatinib plus 5-fluorouracil as a third or subsequent-line treatment option for metastatic colorectal cancer: a phase-II, single-arm, prospective study.
    Chen R, Yang L, Hu S, et al. · Ann Transl Med · 2022 · Derived
    PubMed: PMID 35282086 · NCT03210064 · Colorectal Neoplasms
  49. Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.
    Bao Y, Zhang Z, He X, et al. · Curr Oncol · 2022 · Derived
    PubMed: PMID 36135045 · NCT03080805
  50. A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma.
    Xu Y, Dong B, Zhu W, et al. · Clin Cancer Res · 2022 · Background
    PubMed: PMID 35190815 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  51. Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma.
    Xie L, Xu J, Sun X, et al. · Cancer Manag Res · 2022 · Background
    PubMed: PMID 32021426 · NCT03359018 (APFAO) · Osteosarcoma
  52. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.
    Weinberg BA, Xiu J, Lindberg MR, et al. · J Gastrointest Oncol · 2022 · Background
    PubMed: PMID 31392046 · NCT04720131 · Biliary Tract Neoplasms
  53. Chordoma.
    Ulici V, Hart J · Arch Pathol Lab Med · 2022 · Background
    PubMed: PMID 34319396 · NCT06140732 · Chordoma
  54. Salvage treatment with apatinib for advanced non-small-cell lung cancer.
    Song Z, Yu X, Lou G, et al. · Onco Targets Ther · 2022 · Background
    PubMed: PMID 28367065 · NCT03709953 (Spark-AL003) · Lung Neoplasms
  55. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
    Somaiah N, Conley AP, Parra ER, et al. · Lancet Oncol · 2022 · Background
    PubMed: PMID 35934010 · NCT06140732 · Chordoma
  56. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
    Gruber JJ, Afghahi A, Timms K, et al. · Nat Cancer · 2022 · Background
    PubMed: PMID 36253484 · NCT07371910 · Breast Neoplasms
  57. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
    DeMaria PJ, Lee-Wisdom K, Donahue RN, et al. · J Immunother Cancer · 2022 · Background
    PubMed: PMID 34479925 · NCT06140732 · Chordoma

2021 (47 papers)

  1. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
    Xie L, Xu J, Sun X, et al. · J Immunother Cancer · 2021 · Trial result
    PubMed: PMID 32376724 · NCT04642664 (ACABC) · Cholangiocarcinoma
  2. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J, Liu Q, Li Y, et al. · J Immunother Cancer · 2021 · Trial result
    PubMed: PMID 32448804 · NCT04642664 (ACABC) · Cholangiocarcinoma
  3. Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan.
    FGM 2025 Workflow Study Group (Alliance nationale des Sciences de la Vie et de la Santé), Auzanneau C, Bacq D, et al. · ESMO Open · 2021 · Trial result
    PubMed: PMID 32713836 · NCT03784014 (MULTISARC) · Neoplasm Metastasis
  4. Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).
    Zhao H, Yao W, Min X, et al. · J Thorac Oncol · 2021 · Derived
    PubMed: PMID 34033974 · NCT02824458
  5. Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer.
    Zhang Z, Zhang Y, Luo F, et al. · Clin Transl Med · 2021 · Derived
    PubMed: PMID 32508029 · NCT02824458
  6. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study.
    Zhang W, Yan C, Zhang T, et al. · Oncoimmunology · 2021 · Derived
    PubMed: PMID 34616588 · NCT03671265 · Esophageal Neoplasms
  7. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B, Qi L, Wang X, et al. · Cancer Commun (Lond) · 2021 · Derived
    PubMed: PMID 33314747 · NCT03603756 · Esophageal Squamous Cell Carcinoma
  8. Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.
    Yu Z, Cai X, Xu Z, et al. · Oncologist · 2021 · Derived
    PubMed: PMID 32533785 · NCT03256721 · Carcinoma, Non-Small-Cell Lung
  9. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Xu B, Yan M, Ma F, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33581774 · NCT03080805
  10. Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.
    Wu S, Zhang L, Li H, et al. · Trials · 2021 · Derived
    PubMed: PMID 32448335 · NCT03932526 · Triple Negative Breast Neoplasms
  11. Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges.
    Vatner R, James CD, Sathiaseelan V, et al. · Pediatr Blood Cancer · 2021 · Derived
    PubMed: PMID 32827353 · NCT03868852
  12. Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies.
    Tian H, Wang X, Lian B, et al. · Front Pharmacol · 2021 · Derived
    PubMed: PMID 34858178 · NCT03955354 · Melanoma
  13. STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial.
    Sonnenblick A, Agbor-Tarh D, de Azambuja E, et al. · Int J Cancer · 2021 · Derived
    PubMed: PMID 33152119 · NCT00490139 (ALTTO) · Breast Neoplasms
  14. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
    Saura C, Oliveira M, Feng YH, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32678716 · NCT01808573 (NALA)
  15. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial.
    Sartore-Bianchi A, Lonardi S, Martino C, et al. · ESMO Open · 2021 · Derived
    PubMed: PMID 32988996 · NCT03225937 (HERACLES) · Colorectal Neoplasms
  16. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Qin S, Li Q, Gu S, et al. · Lancet Gastroenterol Hepatol · 2021 · Derived
    PubMed: PMID 33971141 · NCT02329860 · Carcinoma, Hepatocellular
  17. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
    Moreno-Aspitia A, Holmes EM, Jackisch C, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 33765513 · NCT00490139 (ALTTO) · Breast Neoplasms
  18. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
    Mei K, Qin S, Chen Z, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 33741732 · NCT03092895
  19. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
    Ma X, Li L, Zhang L, et al. · Drug Des Devel Ther · 2021 · Derived
    PubMed: PMID 32158186 · NCT03376958 · Recurrence
  20. Concurrent Apatinib and Brain Radiotherapy in Patients With Brain Metastases From Driver Mutation-negative Non-small-cell Lung Cancer: Study Protocol for an Open-label Randomized Controlled Trial.
    Ma J, Pi G, Bi J, et al. · Clin Lung Cancer · 2021 · Derived
    PubMed: PMID 33187916 · NCT03801200 · Brain Neoplasms
  21. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.
    Luvira V, Satitkarnmanee E, Pugkhem A, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34515993 · NCT03609489 · Biliary Tract Neoplasms
  22. A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.
    Liu Y, Hu X, Jiang J, et al. · Oncologist · 2021 · Derived
    PubMed: PMID 32250517 · NCT02995187 · Small Cell Lung Carcinoma
  23. Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer.
    Lin YS, Zhang X, Wang C, et al. · J Clin Endocrinol Metab · 2021 · Derived
    PubMed: PMID 33769497 · NCT02731352 · Thyroid Neoplasms
  24. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
    Lan C, Shen J, Wang Y, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33052760 · NCT03816553 · Uterine Cervical Neoplasms
  25. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
    Johnston SRD, Hegg R, Im SA, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32822287 · NCT01160211 · Breast Neoplasms
  26. Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial.
    Huang X, Xie C, Tang J, et al. · BMC Med · 2021 · Derived
    PubMed: PMID 33012286 · NCT02867956 · Ovarian Neoplasms
  27. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
    Hoon SN, Lau PK, White AM, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34037241 · NCT01050322 (GLICO-0801) · Breast Neoplasms
  28. Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
    Haddad TC, He J, O'Sullivan CC, et al. · Breast Cancer Res Treat · 2021 · Derived
    PubMed: PMID 33852121 · NCT00684983 · Breast Neoplasms
  29. Efficacy and safety of neoadjuvant chemoradiotherapy plus apatinib for patients with locally advanced, HER2-negative, Siewert's type II-III adenocarcinoma of esophagogastric junction: a single-arm, open-label, phase II trial.
    Guo H, Li Y, Lin C, et al. · Am J Transl Res · 2021 · Derived
    PubMed: PMID 34540013 · NCT03349866
  30. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.
    Guarneri V, Dieci MV, Griguolo G, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 34153715 · NCT00429299 (CHERLOB) · Breast Neoplasms
  31. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
    Fernandez-Martinez A, Krop IE, Hillman DW, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 33095682 · NCT00770809 · Breast Neoplasms
  32. Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial.
    Fan Y, Zhao J, Wang Q, et al. · J Thorac Oncol · 2021 · Derived
    PubMed: PMID 33166719 · NCT03417895 (PASSION) · Small Cell Lung Carcinoma
  33. Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis.
    Deng Z, Qin Y, Liu Y, et al. · Clin Lung Cancer · 2021 · Derived
    PubMed: PMID 33067126 · NCT02824458
  34. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
    Dai MS, Feng YH, Chen SW, et al. · Breast Cancer Res Treat · 2021 · Derived
    PubMed: PMID 34553296 · NCT01808573 (NALA)
  35. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.
    Cooper O, Bonert VS, Rudnick J, et al. · J Clin Endocrinol Metab · 2021 · Derived
    PubMed: PMID 33150390 · NCT00939523 · Pituitary Neoplasms
  36. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial.
    Cheng H, Zong L, Kong Y, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34624252 · NCT04047017 (GTN) · Recurrence
  37. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial.
    Chen X, Qin S, Gu S, et al. · Int J Cancer · 2021 · Derived
    PubMed: PMID 34309846 · NCT03092895
  38. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
    Sung H, Ferlay J, Siegel RL, et al. · CA Cancer J Clin · 2021 · Background
    PubMed: PMID 33538338 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  39. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies.
    Piha-Paul SA, Oh DY, Ueno M, et al. · Int J Cancer · 2021 · Background
    PubMed: PMID 32359091 · NCT04720131 · Biliary Tract Neoplasms
  40. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
    Kim RD, Chung V, Alese OB, et al. · JAMA Oncol · 2021 · Background
    PubMed: PMID 32352498 · NCT04720131 · Biliary Tract Neoplasms
  41. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study).
    Hulshof MCCM, Geijsen ED, Rozema T, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 34101496 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  42. The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma.
    Hu L, Kong Z, Meng Q, et al. · Med Sci Monit · 2021 · Background
    PubMed: PMID 33243967 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  43. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
    Finn RS, Ikeda M, Zhu AX, et al. · J Clin Oncol · 2021 · Background
    PubMed: PMID 32716739 · NCT05062837 · Carcinoma, Hepatocellular
  44. A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11).
    Chu L, Chen Y, Liu Q, et al. · Oncologist · 2021 · Background
    PubMed: PMID 33393167 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  45. Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy.
    Chi D, Chen B, Guo S, et al. · Aging (Albany NY) · 2021 · Background
    PubMed: PMID 33713398 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  46. Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review.
    Chen Y, Jia Y, Liu Q, et al. · Ann Palliat Med · 2021 · Background
    PubMed: PMID 34263614 · NCT06140732 · Chordoma
  47. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
    Chen X, Wu X, Wu H, et al. · J Immunother Cancer · 2021 · Background
    PubMed: PMID 33172881 · NCT04720131 · Biliary Tract Neoplasms

2020 (42 papers)

  1. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
    Qin S, Ren Z, Meng Z, et al. · Lancet Oncol · 2020 · Trial result
    PubMed: PMID 32112738 · NCT04642664 (ACABC) · Cholangiocarcinoma
  2. Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?
    Franses JW, Hong TS, Zhu AX, et al. · Lancet Gastroenterol Hepatol · 2020 · Trial result
    PubMed: PMID 31109809 · NCT04642664 (ACABC) · Cholangiocarcinoma
  3. Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
    Zheng Y, Yang X, Yan C, et al. · Eur J Cancer · 2020 · Derived
    PubMed: PMID 32171104 · NCT04208347 · Adenocarcinoma
  4. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z, Luo F, Zhang Y, et al. · Cancer Commun (Lond) · 2020 · Derived
    PubMed: PMID 31699150 · NCT02824458
  5. Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
    Zhang X, Xiong Y, Xia Q, et al. · JAMA Netw Open · 2020 · Derived
    PubMed: PMID 32191330 · NCT03652857
  6. Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.
    Xu Y, Huang Z, Lu H, et al. · Br J Cancer · 2020 · Derived
    PubMed: PMID 31523058 · NCT02945852 · Small Cell Lung Carcinoma
  7. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
    Xu J, Zhang Y, Jia R, et al. · Clin Cancer Res · 2020 · Derived
    PubMed: PMID 30348638 · NCT02942329 · Stomach Neoplasms
  8. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
    Veeraraghavan J, De Angelis C, Mao R, et al. · Ann Oncol · 2020 · Derived
    PubMed: PMID 30903140 · NCT00548184 · Breast Neoplasms
  9. Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16).
    Sim SH, Park IH, Jung KH, et al. · Br J Cancer · 2020 · Derived
    PubMed: PMID 31690831 · NCT01730677 (LV) · Breast Neoplasms
  10. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
    Rimawi MF, Niravath P, Wang T, et al. · Clin Cancer Res · 2020 · Derived
    PubMed: PMID 31662331 · NCT00999804 (HELEX) · Breast Neoplasms
  11. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
    Patel TA, Ensor JE, Creamer SL, et al. · Breast Cancer Res · 2020 · Derived
    PubMed: PMID 31477168 · NCT02073487 (TEAL) · Breast Neoplasms
  12. Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases.
    Morikawa A, de Stanchina E, Pentsova E, et al. · Clin Cancer Res · 2020 · Derived
    PubMed: PMID 30988080 · NCT02650752 · Breast Neoplasms
  13. A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.
    Lynce F, Wang H, Petricoin EF, et al. · Cancer Chemother Pharmacol · 2020 · Derived
    PubMed: PMID 31538230 · NCT01497626
  14. Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).
    Hurvitz SA, Caswell-Jin JL, McNamara KL, et al. · Nat Commun · 2020 · Derived
    PubMed: PMID 33203854 · NCT00769470 · Breast Neoplasms
  15. Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.
    Holmes EM, Bradbury I, Williams LS, et al. · Ann Oncol · 2020 · Derived
    PubMed: PMID 31240310 · NCT00490139 (ALTTO) · Breast Neoplasms
  16. An update on emerging drugs in osteosarcoma: towards tailored therapies?
    Hattinger CM, Patrizio MP, Magagnoli F, et al. · Expert Opin Emerg Drugs · 2020 · Derived
    PubMed: PMID 31401903 · NCT03163381 · Osteosarcoma
  17. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
    Eiger D, Pondé NF, Agbor-Tarh D, et al. · Br J Cancer · 2020 · Derived
    PubMed: PMID 32203207 · NCT00490139 (ALTTO) · Breast Neoplasms
  18. The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors.
    Coker SA, Hurwitz HI, Sharma S, et al. · Cancer Chemother Pharmacol · 2020 · Derived
    PubMed: PMID 31187169 · NCT01328054 · Neoplasms
  19. Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction.
    Allum WH, Smyth EC, Blazeby JM, et al. · Br J Surg · 2020 · Derived
    PubMed: PMID 31268180 · NCT00450203 (ST03)
  20. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis.
    Zhang XP, Chai ZT, Gao YZ, et al. · HPB (Oxford) · 2020 · Background
    PubMed: PMID 31153833 · NCT04521153 · Carcinoma, Hepatocellular
  21. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
    Xie L, Xu J, Sun X, et al. · Oncologist · 2020 · Background
    PubMed: PMID 30559126 · NCT04690231 · Osteosarcoma
  22. Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy.
    Wang D, Jia W, Wang Z, et al. · Onco Targets Ther · 2020 · Background
    PubMed: PMID 31410023 · NCT04521153 · Carcinoma, Hepatocellular
  23. Cancer statistics, 2020.
    Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2020 · Background
    PubMed: PMID 31912902 · NCT04338438 · Stomach Neoplasms
  24. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
    Shiono A, Kaira K, Mouri A, et al. · Thorac Cancer · 2020 · Background
    PubMed: PMID 30809973 · NCT05029453 · Stomach Neoplasms
  25. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
    Reck M, Mok TSK, Nishio M, et al. · Lancet Respir Med · 2020 · Background
    PubMed: PMID 30922878 · NCT04548271 · Nasopharyngeal Carcinoma
  26. PD-1 Blockade in Advanced Adrenocortical Carcinoma.
    Raj N, Zheng Y, Kelly V, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 31644329 · NCT06831175 · Adrenal Gland Neoplasms
  27. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.
    Mazzaferro V, Citterio D, Bhoori S, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 32615109 · NCT05713994 (CCGLC-001) · Carcinoma, Hepatocellular
  28. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Liu JF, Barry WT, Birrer M, et al. · Ann Oncol · 2020 · Background
    PubMed: PMID 30753272 · NCT07371910 · Breast Neoplasms
  29. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.
    Liu C, Jia Q, Wei H, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 32888455 · NCT06140732 · Chordoma
  30. Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome.
    Lin CY, Chen YJ, Hsieh MH, et al. · J Thorac Dis · 2020 · Background
    PubMed: PMID 28203414 · NCT03709953 (Spark-AL003) · Lung Neoplasms
  31. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
    Liang W, Guan W, Chen R, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 32066541 · NCT04338438 · Stomach Neoplasms
  32. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
    Kim ST, Kang JH, Lee J, et al. · Ann Oncol · 2020 · Background
    PubMed: PMID 30785198 · NCT04720131 · Biliary Tract Neoplasms
  33. Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.
    Kim R, Coppola D, Wang E, et al. · Oncotarget · 2020 · Background
    PubMed: PMID 29805739 · NCT04720131 · Biliary Tract Neoplasms
  34. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature.
    Kim C, Rajan A, DeBrito PA, et al. · Transl Lung Cancer Res · 2020 · Background
    PubMed: PMID 28149767 · NCT03709953 (Spark-AL003) · Lung Neoplasms
  35. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
    Kawazoe A, Fukuoka S, Nakamura Y, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 32589866 · NCT05025033 · Stomach Neoplasms
  36. Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer.
    Kaufman PA, Wildiers H, Freyer G, et al. · Clin Breast Cancer · 2020 · Background
    PubMed: PMID 30420181 · NCT00807859 · Breast Neoplasms
  37. Apatinib enhances the radiosensitivity of the esophageal cancer cell line KYSE-150 by inducing apoptosis and cell cycle redistribution.
    Hu L, Sun F, Sun Z, et al. · Oncol Lett · 2020 · Background
    PubMed: PMID 30675220 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  38. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
    He M, Li Q, Zou R, et al. · JAMA Oncol · 2020 · Background
    PubMed: PMID 31070690 · NCT05313282 (TRIPLET-III)
  39. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.
    Habra MA, Stephen B, Campbell M, et al. · J Immunother Cancer · 2020 · Background
    PubMed: PMID 31533818 · NCT06831175 · Adrenal Gland Neoplasms
  40. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS, Qin S, Ikeda M, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32402160 · NCT05062837 · Carcinoma, Hepatocellular
  41. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F, Mir O, Boudou-Rouquette P, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 30477937 · NCT07479732 · Osteosarcoma
  42. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.
    Akateh C, Black SM, Conteh L, et al. · World J Gastroenterol · 2020 · Background
    PubMed: PMID 31391767 · NCT04521153 · Carcinoma, Hepatocellular

2019 (28 papers)

  1. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
    Scott LJ · Drugs · 2019 · Trial result
    PubMed: PMID 29663291 · NCT04642664 (ACABC) · Cholangiocarcinoma
  2. Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials.
    Liang L, Wen Y, Hu R, et al. · Cancer Immunol Immunother · 2019 · Trial result
    PubMed: PMID 31451841 · NCT04642664 (ACABC) · Cholangiocarcinoma
  3. Pilot Dose Comparison of Apatinib in Chinese Patients With Progressive Radioiodine-Refractory Differentiated Thyroid Cancer.
    Zhang X, Wang C, Lin Y, et al. · J Clin Endocrinol Metab · 2019 · Derived
    PubMed: PMID 30053006 · NCT02731352 · Thyroid Neoplasms
  4. Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study.
    Yardley DA, Hart LL, Ward PJ, et al. · Clin Breast Cancer · 2019 · Derived
    PubMed: PMID 29678476 · NCT01934894
  5. A Phase II Clinical Trial of Apatinib in Pretreated Advanced Non-squamous Non-small-cell Lung Cancer.
    Wu F, Zhang S, Xiong A, et al. · Clin Lung Cancer · 2019 · Derived
    PubMed: PMID 30026059 · NCT02515435 · Carcinoma, Non-Small-Cell Lung
  6. US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
    Wedam SB, Beaver JA, Amiri-Kordestani L, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29522361 · NCT00073528 · Breast Neoplasms
  7. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
    Untch M, von Minckwitz G, Gerber B, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29543566 · NCT00567554 (GeparQuinto) · Breast Neoplasms
  8. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
    Powles RL, Redmond D, Sotiriou C, et al. · JAMA Oncol · 2019 · Derived
    PubMed: PMID 29902299 · NCT00553358 (Neo ALTTO) · Breast Neoplasms
  9. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Nuciforo P, Pascual T, Cortés J, et al. · Ann Oncol · 2019 · Derived
    PubMed: PMID 29045543 · NCT01973660 (PAMELA) · Breast Neoplasms
  10. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
    Lan CY, Wang Y, Xiong Y, et al. · Lancet Oncol · 2019 · Derived
    PubMed: PMID 30082170 · NCT02867956 · Ovarian Neoplasms
  11. Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study.
    Labots M, Van der Mijn JC, Dekker H, et al. · Oncologist · 2019 · Derived
    PubMed: PMID 30018133 · NCT01190241 (TSAP) · Neoplasm Metastasis
  12. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
    Jiang Q, Zhang NL, Ma DY, et al. · Medicine (Baltimore) · 2019 · Derived
    PubMed: PMID 31261514 · NCT03416231
  13. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
    Fasching PA, Loibl S, Hu C, et al. · J Clin Oncol · 2019 · Derived
    PubMed: PMID 29791287 · NCT00567554 (GeparQuinto) · Breast Neoplasms
  14. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Zhou M, Wang H, Zeng X, et al. · Lancet · 2019 · Background
    PubMed: PMID 31248666 · NCT04521153 · Carcinoma, Hepatocellular
  15. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.
    Yan Y, Cao S, Liu X, et al. · JCI Insight · 2019 · Background
    PubMed: PMID 29669928 · NCT05029453 · Stomach Neoplasms
  16. Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.
    Wu F, Zhang S, Gao G, et al. · Cancer Biol Ther · 2019 · Background
    PubMed: PMID 29261000 · NCT03547804 (MK 01) · Small Cell Lung Carcinoma
  17. Cancer statistics, 2018.
    Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2019 · Background
    PubMed: PMID 29313949 · NCT04720131 · Biliary Tract Neoplasms
  18. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
    Ray-Coquard I, Pautier P, Pignata S, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31851799 · NCT07371910 · Breast Neoplasms
  19. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
    Ma BBY, Lim WT, Goh BC, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 29584545 · NCT04547088 · Nasopharyngeal Carcinoma
  20. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Lyu N, Kong Y, Mu L, et al. · J Hepatol · 2019 · Background
    PubMed: PMID 29471013 · NCT04191889 (TRIPLET)
  21. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
    Johnston SRD, Hegg R, Im SA, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 29244528 · NCT01160211 · Breast Neoplasms
  22. Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?
    Italiano A · Curr Treat Options Oncol · 2019 · Background
    PubMed: PMID 30523434 · NCT03784014 (MULTISARC) · Neoplasm Metastasis
  23. Previous Immune Checkpoint Inhibitor Treatment to Increase the Efficacy of Docetaxel and Ramucirumab Combination Chemotherapy.
    Harada D, Takata K, Mori S, et al. · Anticancer Res · 2019 · Background
    PubMed: PMID 31519605 · NCT05029453 · Stomach Neoplasms
  24. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    González-Martín A, Pothuri B, Vergote I, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31562799 · NCT06255392
  25. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
    Fuchs CS, Doi T, Jang RW, et al. · JAMA Oncol · 2019 · Background
    PubMed: PMID 29543932 · NCT05025033 · Stomach Neoplasms
  26. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
    Ferlay J, Colombet M, Soerjomataram I, et al. · Int J Cancer · 2019 · Background
    PubMed: PMID 30350310 · NCT04521153 · Carcinoma, Hepatocellular
  27. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
    Fang W, Yang Y, Ma Y, et al. · Lancet Oncol · 2019 · Background
    PubMed: PMID 30213452 · NCT04547088 · Nasopharyngeal Carcinoma
  28. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
    Bang YJ, Kang YK, Catenacci DV, et al. · Gastric Cancer · 2019 · Background
    PubMed: PMID 30911859 · NCT05025033 · Stomach Neoplasms

2018 (21 papers)

  1. Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
    Webber K, Friedlander M · Best Pract Res Clin Obstet Gynaecol · 2018 · Trial result
    PubMed: PMID 28027849 · NCT03587129 · Ovarian Neoplasms
  2. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
    Roncolato FT, Joly F, O'Connell R, et al. · Oncologist · 2018 · Trial result
    PubMed: PMID 28596446 · NCT03587129 · Ovarian Neoplasms
  3. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
    Oronsky B, Ray CM, Spira AI, et al. · Med Oncol · 2018 · Trial result
    PubMed: PMID 28444622 · NCT03587129 · Ovarian Neoplasms
  4. Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab).
    Ho D, Huang J, Chapman JW, et al. · Breast Cancer Res Treat · 2018 · Trial result
    PubMed: PMID 28484925 · NCT00667251 · Breast Neoplasms
  5. A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
    Chia SK, Ellard SL, Mates M, et al. · Breast Cancer Res · 2018 · Trial result
    PubMed: PMID 28464908 · NCT01138384 · Breast Neoplasms
  6. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S, Eustace AJ, Fay J, et al. · Breast Cancer Res · 2018 · Derived
    PubMed: PMID 28750640 · NCT01485926 (TCHL Phase II) · Breast Neoplasms
  7. A Phase II Study with Lead-In Safety Cohort of 5-Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2-Positive Esophagogastric Adenocarcinomas.
    Shepard G, Arrowsmith ER, Murphy P, et al. · Oncologist · 2018 · Derived
    PubMed: PMID 28765502 · NCT01769508
  8. Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients.
    Koch KM, Ferron-Brady G, Lemmon C, et al. · Clin Pharmacol Drug Dev · 2018 · Derived
    PubMed: PMID 27140800 · NCT00996762 · Breast Neoplasms
  9. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
    Xie L, Guo W, Wang Y, et al. · BMC Cancer · 2018 · Background
    PubMed: PMID 29625604 · NCT04260113 (AIAC) · Drug-Related Side Effects and Adverse Reactions
  10. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
    Tang Y, Liu Z, Zou Z, et al. · Biomed Res Int · 2018 · Background
    PubMed: PMID 29967789 · NCT06831175 · Adrenal Gland Neoplasms
  11. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
    Sun C, Yin J, Fang Y, et al. · Cancer Cell · 2018 · Background
    PubMed: PMID 29533782 · NCT07371910 · Breast Neoplasms
  12. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    Severson TM, Wolf DM, Yau C, et al. · Breast Cancer Res · 2018 · Background
    PubMed: PMID 28851423 · NCT07371910 · Breast Neoplasms
  13. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Schvartsman G, Peng SA, Bis G, et al. · Lung Cancer · 2018 · Background
    PubMed: PMID 29191606 · NCT05029453 · Stomach Neoplasms
  14. Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    Park SE, Lee SH, Ahn JS, et al. · J Thorac Oncol · 2018 · Background
    PubMed: PMID 29101058 · NCT05029453 · Stomach Neoplasms
  15. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    Litton JK, Rugo HS, Ettl J, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 30110579 · NCT07371910 · Breast Neoplasms
  16. Lymphoepithelioma-Like Carcinoma of the Esophagus: A Rare Tumor.
    Khokhar N, Nasir H, Amir M, et al. · J Coll Physicians Surg Pak · 2018 · Background
    PubMed: PMID 28969745 · NCT03709953 (Spark-AL003) · Lung Neoplasms
  17. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Kang YK, Boku N, Satoh T, et al. · Lancet · 2018 · Background
    PubMed: PMID 28993052 · NCT05025033 · Stomach Neoplasms
  18. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.
    Jusakul A, Cutcutache I, Yong CH, et al. · Cancer Discov · 2018 · Background
    PubMed: PMID 28667006 · NCT04720131 · Biliary Tract Neoplasms
  19. Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone.
    Jo VY, Doyle LA · Surg Oncol Clin N Am · 2018 · Background
    PubMed: PMID 27591490 · NCT03104335 · Sarcoma
  20. Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients.
    Huang L, Wei Y, Shen S, et al. · Oncotarget · 2018 · Background
    PubMed: PMID 27793017 · NCT03547804 (MK 01) · Small Cell Lung Carcinoma
  21. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial.
    Chen Q, Shu C, Laurence AD, et al. · Gut · 2018 · Background
    PubMed: PMID 29802174 · NCT04521153 · Carcinoma, Hepatocellular

2017 (29 papers)

  1. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A, Trusolino L, Martino C, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 27108243 · NCT03225937 (HERACLES) · Colorectal Neoplasms
  2. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
    Rustin G, Vergote I, Micha JP, et al. · Gynecol Oncol · 2017 · Trial result
    PubMed: PMID 28935273 · NCT03587129 · Ovarian Neoplasms
  3. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S, Chen B, Burugu S, et al. · JAMA Oncol · 2017 · Trial result
    PubMed: PMID 28750133 · NCT00667251 · Breast Neoplasms
  4. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M, Rezai K, Isambert N, et al. · Eur J Cancer · 2017 · Trial result
    PubMed: PMID 28950146 · NCT01589861 (PIKHER2) · Breast Neoplasms
  5. Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.
    Belin L, Kamal M, Mauborgne C, et al. · Ann Oncol · 2017 · Trial result
    PubMed: PMID 27993804 · NCT01771458 (SHIVA) · Neoplasm Metastasis
  6. A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study.
    Wang L, Liang L, Yang T, et al. · Medicine (Baltimore) · 2017 · Derived
    PubMed: PMID 29245310 · NCT02848794 · Glioma
  7. Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
    Rocca A, Cecconetto L, Passardi A, et al. · Cancer Chemother Pharmacol · 2017 · Derived
    PubMed: PMID 28341957 · NCT02131506 (CAELYX) · Breast Neoplasms
  8. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
    Llombart-Cussac A, Cortés J, Paré L, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28238593 · NCT01973660 (PAMELA) · Breast Neoplasms
  9. A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.
    LaBonte MJ, Yang D, Zhang W, et al. · Mol Cancer Ther · 2017 · Derived
    PubMed: PMID 27325685 · NCT00526669 · Stomach Neoplasms
  10. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V, Miles D, Verma S, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28526536 · NCT00829166 (EMILIA) · Breast Neoplasms
  11. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.
    Cunningham D, Stenning SP, Smyth EC, et al. · Lancet Oncol · 2017 · Derived
    PubMed: PMID 28163000 · NCT00450203 (ST03)
  12. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.
    Chu MP, Hecht JR, Slamon D, et al. · JAMA Oncol · 2017 · Derived
    PubMed: PMID 27737436 · NCT00680901 · Neoplasms
  13. The challenge of screening for early gastric cancer in China.
    Zong L, Abe M, Seto Y, et al. · Lancet · 2017 · Background
    PubMed: PMID 27894662 · NCT04338438 · Stomach Neoplasms
  14. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT).
    Wong AC, Watson SP, Pitroda SP, et al. · Cancer · 2017 · Background
    PubMed: PMID 27206146 · NCT03457467 · Breast Neoplasms
  15. [Pathologic response and changes of serum VEGF during chemoradiotherapy may predict prognosis in non-surgical patients with esophageal carcinoma].
    Wang J, Yu JP, Wang JL, et al. · Zhonghua Zhong Liu Za Zhi · 2017 · Background
    PubMed: PMID 27531478 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  16. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.
    Suntharalingam M, Winter K, Ilson D, et al. · JAMA Oncol · 2017 · Background
    PubMed: PMID 28687830 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  17. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project.
    Sano T, Coit DG, Kim HH, et al. · Gastric Cancer · 2017 · Background
    PubMed: PMID 26897166 · NCT03229096 · Stomach Neoplasms
  18. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    Robson M, Im SA, Senkus E, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 28578601 · NCT07371910 · Breast Neoplasms
  19. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A, Cheang MC, Galván P, et al. · JAMA Oncol · 2017 · Background
    PubMed: PMID 27281556 · NCT00073528 · Breast Neoplasms
  20. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.
    Peng H, Zhang Q, Li J, et al. · Oncotarget · 2017 · Background
    PubMed: PMID 26967384 · NCT03427242 · Biliary Tract Neoplasms
  21. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
    Manegold C, Dingemans AC, Gray JE, et al. · J Thorac Oncol · 2017 · Background
    PubMed: PMID 27729297 · NCT04720131 · Biliary Tract Neoplasms
  22. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F, Zhu T, Cao B, et al. · Eur J Cancer · 2017 · Background
    PubMed: PMID 28822888 · NCT03547804 (MK 01) · Small Cell Lung Carcinoma
  23. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
    Kim KL, Suh W · Invest Ophthalmol Vis Sci · 2017 · Background
    PubMed: PMID 28715845 · NCT03547804 (MK 01) · Small Cell Lung Carcinoma
  24. Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage.
    Jeong JH, Nguyen HK, Lee JE, et al. · Int J Nanomedicine · 2017 · Background
    PubMed: PMID 27462154 · NCT03709953 (Spark-AL003) · Lung Neoplasms
  25. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
    Ito S, Sano T, Mizusawa J, et al. · Gastric Cancer · 2017 · Background
    PubMed: PMID 27299887 · NCT03229096 · Stomach Neoplasms
  26. Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer.
    Hughes PE, Caenepeel S, Wu LC, et al. · Trends Immunol · 2017 · Background
    PubMed: PMID 27216414 · NCT05025033 · Stomach Neoplasms
  27. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
    Hsu C, Lee SH, Ejadi S, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28837405 · NCT04548271 · Nasopharyngeal Carcinoma
  28. The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature.
    Ding L, Li QJ, You KY, et al. · Medicine (Baltimore) · 2017 · Background
    PubMed: PMID 27196461 · NCT03376191 · Lung Neoplasms
  29. Soft tissue sarcoma - A review of presentation, management and outcomes in 110 patients.
    Bains R, Magdum A, Bhat W, et al. · Surgeon · 2017 · Background
    PubMed: PMID 25261278 · NCT03104335 · Sarcoma

2016 (36 papers)

  1. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
    Piccart-Gebhart M, Holmes E, Baselga J, et al. · J Clin Oncol · 2016 · Trial result
    PubMed: PMID 26598744 · NCT03085368 · Breast Neoplasms
  2. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
    Peeters M, Oliner KS, Price TJ, et al. · Clin Cancer Res · 2016 · Trial result
    PubMed: PMID 26341920 · NCT02829385 · Colorectal Neoplasms
  3. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J, Qin S, Xu J, et al. · J Clin Oncol · 2016 · Trial result
    PubMed: PMID 26884585 · NCT02989259 · Head and Neck Neoplasms
  4. Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
    Bonnefoi H, Jacot W, Saghatchian M, et al. · Ann Oncol · 2016 · Trial result
    PubMed: PMID 25467016 · NCT00450892 · Breast Neoplasms
  5. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
    Thomas A, Chen Y, Steinberg SM, et al. · Oncotarget · 2016 · Derived
    PubMed: PMID 26028668 · NCT01306045 · Carcinoma, Non-Small-Cell Lung
  6. Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.
    Spector NL, Robertson FC, Bacus S, et al. · PLoS One · 2016 · Derived
    PubMed: PMID 26571496 · NCT00359190 · Breast Neoplasms
  7. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R, Denkert C, Campbell C, et al. · JAMA Oncol · 2016 · Derived
    PubMed: PMID 26181252 · NCT00553358 (Neo ALTTO) · Breast Neoplasms
  8. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
    Nuciforo PG, Aura C, Holmes E, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 25851628 · NCT00553358 (Neo ALTTO) · Breast Neoplasms
  9. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C, Delord JP, Gonçalves A, et al. · Lancet Oncol · 2016 · Derived
    PubMed: PMID 26342236 · NCT01771458 (SHIVA) · Neoplasm Metastasis
  10. Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.
    Janni W, Sarosiek T, Karaszewska B, et al. · Breast · 2016 · Derived
    PubMed: PMID 26384789 · NCT01013740 (VITAL) · Breast Neoplasms
  11. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.
    Iyengar NM, Fornier MN, Sugarman SM, et al. · Clin Breast Cancer · 2016 · Derived
    PubMed: PMID 26454612 · NCT01827163
  12. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
    Hecht JR, Bang YJ, Qin SK, et al. · J Clin Oncol · 2016 · Derived
    PubMed: PMID 26628478 · NCT00680901 · Neoplasms
  13. Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
    Harrington K, Temam S, Mehanna H, et al. · J Clin Oncol · 2016 · Derived
    PubMed: PMID 26527790 · NCT00424255 · Head and Neck Neoplasms
  14. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
    Guarneri V, Dieci MV, Frassoldati A, et al. · Oncologist · 2016 · Derived
    PubMed: PMID 26245675 · NCT00429299 (CHERLOB) · Breast Neoplasms
  15. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
    Carey LA, Berry DA, Cirrincione CT, et al. · J Clin Oncol · 2016 · Derived
    PubMed: PMID 26527775 · NCT00770809 · Breast Neoplasms
  16. HER2 as a target in invasive urothelial carcinoma.
    Bellmunt J, Werner L, Bamias A, et al. · Cancer Med · 2016 · Derived
    PubMed: PMID 25720673 · NCT00949455 (LaMB) · Urinary Bladder Neoplasms
  17. Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
    Agelaki S, Kalykaki A, Markomanolaki H, et al. · PLoS One · 2016 · Derived
    PubMed: PMID 26083256 · NCT00694252 · Breast Neoplasms
  18. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus.
    Zhang ZM, Lai EC, Zhang C, et al. · Int J Surg · 2016 · Background
    PubMed: PMID 26026424 · NCT03261791 · Carcinoma, Hepatocellular
  19. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
    Zhang L, Huang Y, Hong S, et al. · Lancet · 2016 · Background
    PubMed: PMID 27567279 · NCT04547088 · Nasopharyngeal Carcinoma
  20. Apatinib for molecular targeted therapy in tumor.
    Zhang H · Drug Des Devel Ther · 2016 · Background
    PubMed: PMID 26622168 · NCT03376191 · Lung Neoplasms
  21. Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
    Xu JL, Jin B, Ren ZH, et al. · PLoS One · 2016 · Background
    PubMed: PMID 26147288 · NCT02704767 · Lung Neoplasms
  22. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
    Wang-Gillam A, Li CP, Bodoky G, et al. · Lancet · 2016 · Background
    PubMed: PMID 26615328 · NCT07479732 · Osteosarcoma
  23. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
    Valtorta E, Martino C, Sartore-Bianchi A, et al. · Mod Pathol · 2016 · Background
    PubMed: PMID 26449765 · NCT03225937 (HERACLES) · Colorectal Neoplasms
  24. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD, Jones RL, Van Tine BA, et al. · Lancet · 2016 · Background
    PubMed: PMID 27291997 · NCT03104335 · Sarcoma
  25. RECIST for Response (Clinical and Imaging) in Neoadjuvant Clinical Trials in Operable Breast Cancer.
    Semiglazov V · J Natl Cancer Inst Monogr · 2016 · Background
    PubMed: PMID 26063880 · NCT02711007 · Neoplasm Metastasis
  26. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
    Roviello G, Ravelli A, Polom K, et al. · Cancer Lett · 2016 · Background
    PubMed: PMID 26797419 · NCT04338438 · Stomach Neoplasms
  27. Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
    Ramlau R, Thomas M, Novello S, et al. · Clin Lung Cancer · 2016 · Background
    PubMed: PMID 25700774 · NCT00528281 · Carcinoma, Non-Small-Cell Lung
  28. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
    Kataoka K, Tokunaga M, Mizusawa J, et al. · Jpn J Clin Oncol · 2016 · Background
    PubMed: PMID 26355164 · NCT03229096 · Stomach Neoplasms
  29. Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
    Fukuchi M, Ishiguro T, Ogata K, et al. · Ann Surg Oncol · 2016 · Background
    PubMed: PMID 25663597 · NCT03007446 · Stomach Neoplasms
  30. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
    Fujitani K, Yang HK, Mizusawa J, et al. · Lancet Oncol · 2016 · Background
    PubMed: PMID 26822397 · NCT03229096 · Stomach Neoplasms
  31. Lung cancer epidemiology: contemporary and future challenges worldwide.
    Didkowska J, Wojciechowska U, Mańczuk M, et al. · Ann Transl Med · 2016 · Background
    PubMed: PMID 27195268 · NCT03376191 · Lung Neoplasms
  32. Cancer statistics in China, 2015.
    Chen W, Zheng R, Baade PD, et al. · CA Cancer J Clin · 2016 · Background
    PubMed: PMID 26808342 · NCT04521153 · Carcinoma, Hepatocellular
  33. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J, Takayama T, Mazzaferro V, et al. · Lancet Oncol · 2016 · Background
    PubMed: PMID 26361969 · NCT04521153 · Carcinoma, Hepatocellular
  34. Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial.
    Brodowicz T, Liegl-Atzwager B, Tresch E, et al. · BMC Cancer · 2016 · Background
    PubMed: PMID 25884155 · NCT03104335 · Sarcoma
  35. Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors.
    Aras M, Erdil TY, Dane F, et al. · Nucl Med Commun · 2016 · Background
    PubMed: PMID 26440568 · NCT02711007 · Neoplasm Metastasis
  36. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
    Apetoh L, Ladoire S, Coukos G, et al. · Ann Oncol · 2016 · Background
    PubMed: PMID 25922066 · NCT05025033 · Stomach Neoplasms

2015 (42 papers)

  1. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH, van Tinteren H, May A, et al. · Lancet · 2015 · Trial result
    PubMed: PMID 25862517 · NCT02829385 · Colorectal Neoplasms
  2. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.
    Scott AJ, Messersmith WA, Jimeno A, et al. · Drugs Today (Barc) · 2015 · Trial result
    PubMed: PMID 26020064 · NCT03365765
  3. Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.
    Okamoto I, Miyazaki M, Takeda M, et al. · J Thorac Oncol · 2015 · Trial result
    PubMed: PMID 25299232 · NCT02733107 · Carcinoma, Non-Small-Cell Lung
  4. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. · J Clin Oncol · 2015 · Trial result
    PubMed: PMID 25366685 · NCT03587129 · Ovarian Neoplasms
  5. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
    Hudis C, Swanton C, Janjigian YY, et al. · Breast Cancer Res · 2015 · Trial result
    PubMed: PMID 24252402 · NCT00963547 · Breast Neoplasms
  6. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
    Gelmon KA, Boyle FM, Kaufman B, et al. · J Clin Oncol · 2015 · Trial result
    PubMed: PMID 25779558 · NCT00667251 · Breast Neoplasms
  7. Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.
    Xu B, Guan Z, Shen Z, et al. · Breast Cancer Res · 2015 · Derived
    PubMed: PMID 25056500 · NCT00281658 · Breast Neoplasms
  8. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
    von Minckwitz G, Loibl S, Untch M, et al. · Ann Oncol · 2015 · Derived
    PubMed: PMID 25223482 · NCT00567554 (GeparQuinto) · Breast Neoplasms
  9. Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.
    Saleem A, Searle GE, Kenny LM, et al. · EJNMMI Res · 2015 · Derived
    PubMed: PMID 25977884 · NCT01290354 · Neoplasms
  10. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck.
    Psyrri A, Rampias T, Vermorken JB, et al. · Ann Oncol · 2015 · Derived
    PubMed: PMID 25057165 · NCT00387127 · Head and Neck Neoplasms
  11. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Pivot X, Manikhas A, Żurawski B, et al. · J Clin Oncol · 2015 · Derived
    PubMed: PMID 25605838 · NCT00820222 · Breast Neoplasms
  12. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
    Morikawa A, Peereboom DM, Thorsheim HR, et al. · Neuro Oncol · 2015 · Derived
    PubMed: PMID 25015089 · NCT00795678 · Breast Neoplasms
  13. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S, Riera Knorrenschild J, Haag GM, et al. · Eur J Cancer · 2015 · Derived
    PubMed: PMID 25694417 · NCT01145404 (GastroLap)
  14. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
    Lopez-Chavez A, Thomas A, Rajan A, et al. · J Clin Oncol · 2015 · Derived
    PubMed: PMID 25667274 · NCT01306045 · Carcinoma, Non-Small-Cell Lung
  15. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
    Lin NU, Guo H, Yap JT, et al. · J Clin Oncol · 2015 · Derived
    PubMed: PMID 26169615 · NCT00470704 · Breast Neoplasms
  16. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X, Cao J, Hu W, et al. · BMC Cancer · 2015 · Derived
    PubMed: PMID 25376790 · NCT01653561 · Breast Neoplasms
  17. A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study).
    Fumoleau P, Koch KM, Brain E, et al. · Breast · 2015 · Derived
    PubMed: PMID 25065668 · NCT00424164 (LAPATAM) · Breast Neoplasms
  18. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.
    Devriese LA, Koch KM, Mergui-Roelvink M, et al. · Invest New Drugs · 2015 · Derived
    PubMed: PMID 24346280 · NCT00821054 · Breast Neoplasms
  19. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. · Lancet Oncol · 2015 · Derived
    PubMed: PMID 25130998 · NCT00553358 (Neo ALTTO) · Breast Neoplasms
  20. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).
    Burstein HJ, Cirrincione CT, Barry WT, et al. · J Clin Oncol · 2015 · Derived
    PubMed: PMID 25348000 · NCT00390455 · Breast Neoplasms
  21. Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer.
    Boyle FM, Smith IE, O'Shaughnessy J, et al. · Eur J Cancer · 2015 · Derived
    PubMed: PMID 25752740 · NCT00374322 · Breast Neoplasms
  22. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
    Zhou C, Wu YL, Chen G, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 26014294 · NCT02733107 · Carcinoma, Non-Small-Cell Lung
  23. Comparison of ECOG/WHO performance status and ASA score as a measure of functional status.
    Young J, Badgery-Parker T, Dobbins T, et al. · J Pain Symptom Manage · 2015 · Background
    PubMed: PMID 24996034 · NCT02711007 · Neoplasm Metastasis
  24. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H, Muro K, Van Cutsem E, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25240821 · NCT05029453 · Stomach Neoplasms
  25. Global cancer statistics, 2012.
    Torre LA, Bray F, Siegel RL, et al. · CA Cancer J Clin · 2015 · Background
    PubMed: PMID 25651787 · NCT04521153 · Carcinoma, Hepatocellular
  26. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
    Tabernero J, Yoshino T, Cohn AL, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25877855 · NCT03271255 · Colorectal Neoplasms
  27. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).
    Shinoda M, Ando N, Kato K, et al. · Cancer Sci · 2015 · Background
    PubMed: PMID 25640628 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  28. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
    Shi Q, de Gramont A, Grothey A, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 25385741 · NCT05029453 · Stomach Neoplasms
  29. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T, Kato T, Nishio M, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25175099 · NCT02704767 · Lung Neoplasms
  30. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.
    Schöffski P, Cornillie J, Wozniak A, et al. · Oncol Res Treat · 2015 · Background
    PubMed: PMID 24903768 · NCT02711007 · Neoplasm Metastasis
  31. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH, Park SR, Yang HK, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25439693 · NCT04338438 · Stomach Neoplasms
  32. Primary lymphoepithelioma-like carcinoma of the lung: distinct computed tomography features and associated clinical outcomes.
    Mo Y, Shen J, Zhang Y, et al. · J Thorac Imaging · 2015 · Background
    PubMed: PMID 24463405 · NCT03709953 (Spark-AL003) · Lung Neoplasms
  33. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
    Liu JF, Barry WT, Birrer M, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25218906 · NCT06255392
  34. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
    Li H, Takayama K, Wang S, et al. · Cancer Chemother Pharmacol · 2015 · Background
    PubMed: PMID 25344762 · NCT02704767 · Lung Neoplasms
  35. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH, Lee JH, Lim YS, et al. · Gastroenterology · 2015 · Background
    PubMed: PMID 25747273 · NCT04521153 · Carcinoma, Hepatocellular
  36. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.
    Isakoff MS, Bielack SS, Meltzer P, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 26304877 · NCT07479732 · Osteosarcoma
  37. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
    Hall RD, Le TM, Haggstrom DE, et al. · Transl Lung Cancer Res · 2015 · Background
    PubMed: PMID 26629420 · NCT03376191 · Lung Neoplasms
  38. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
    Grignani G, Palmerini E, Ferraresi V, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25498219 · NCT02711007 · Neoplasm Metastasis
  39. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.
    Golden EB, Chhabra A, Chachoua A, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 26095785 · NCT02544737 · Esophageal Neoplasms
  40. Clinical advances in the development of novel VEGFR2 inhibitors.
    Fontanella C, Ongaro E, Bolzonello S, et al. · Ann Transl Med · 2015 · Background
    PubMed: PMID 25568876 · NCT03376191 · Lung Neoplasms
  41. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Borghaei H, Paz-Ares L, Horn L, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26412456 · NCT04720131 · Biliary Tract Neoplasms
  42. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).
    Allemani C, Weir HK, Carreira H, et al. · Lancet · 2015 · Background
    PubMed: PMID 25467588 · NCT04521153 · Carcinoma, Hepatocellular

2014 (44 papers)

  1. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
    Tabernero J, Van Cutsem E, Lakomý R, et al. · Eur J Cancer · 2014 · Trial result
    PubMed: PMID 24140268 · NCT02829385 · Colorectal Neoplasms
  2. Bevacizumab in elderly patients with metastatic colorectal cancer.
    Sclafani F, Cunningham D · J Geriatr Oncol · 2014 · Trial result
    PubMed: PMID 24484722 · NCT02829385 · Colorectal Neoplasms
  3. Cholangiocarcinoma.
    Razumilava N, Gores GJ · Lancet · 2014 · Trial result
    PubMed: PMID 24581682 · NCT04642664 (ACABC) · Cholangiocarcinoma
  4. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
    Pujade-Lauraine E, Hilpert F, Weber B, et al. · J Clin Oncol · 2014 · Trial result
    PubMed: PMID 24637997 · NCT03587129 · Ovarian Neoplasms
  5. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
    Naeim A, Ward PR, Wang HJ, et al. · J Geriatr Oncol · 2014 · Trial result
    PubMed: PMID 24472472 · NCT02829385 · Colorectal Neoplasms
  6. Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.
    Kiss I, Bortlicek Z, Melichar B, et al. · Anticancer Res · 2014 · Trial result
    PubMed: PMID 24511038 · NCT02829385 · Colorectal Neoplasms
  7. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
    Kishiki T, Ohnishi H, Masaki T, et al. · Cancer Chemother Pharmacol · 2014 · Trial result
    PubMed: PMID 24500024 · NCT02829385 · Colorectal Neoplasms
  8. Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy.
    Kara O, Duman BB, Kara B, et al. · Asian Pac J Cancer Prev · 2014 · Trial result
    PubMed: PMID 23464465 · NCT02829385 · Colorectal Neoplasms
  9. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
    Dutton SJ, Ferry DR, Blazeby JM, et al. · Lancet Oncol · 2014 · Trial result
    PubMed: PMID 24950987 · NCT03913182 · Neoplasm Metastasis
  10. "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?
    Davis A, Tinker AV, Friedlander M, et al. · Gynecol Oncol · 2014 · Trial result
    PubMed: PMID 24607285 · NCT03587129 · Ovarian Neoplasms
  11. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.
    Crown J, Kennedy MJ, Tresca P, et al. · Ann Oncol · 2014 · Trial result
    PubMed: PMID 23878115 · NCT00251433 · Breast Neoplasms
  12. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
    Chien AJ, Munster PN, Melisko ME, et al. · J Clin Oncol · 2014 · Trial result
    PubMed: PMID 24711549 · NCT00544804 · Breast Neoplasms
  13. Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.
    Bruera G, Cannita K, Giordano AV, et al. · Biomed Res Int · 2014 · Trial result
    PubMed: PMID 24307987 · NCT02829385 · Colorectal Neoplasms
  14. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.
    Alba E, Albanell J, de la Haba J, et al. · Br J Cancer · 2014 · Trial result
    PubMed: PMID 24457911 · NCT00841828 · Breast Neoplasms
  15. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
    Tan AR, Dowlati A, Stein MN, et al. · Br J Cancer · 2014 · Derived
    PubMed: PMID 24800949 · NCT00388076 · Breast Neoplasms
  16. Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
    Schaid DJ, Spraggs CF, McDonnell SK, et al. · J Clin Oncol · 2014 · Derived
    PubMed: PMID 24687830 · NCT00374322 · Breast Neoplasms
  17. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
    Pierga JY, Bidard FC, Cropet C, et al. · Ann Oncol · 2014 · Derived
    PubMed: PMID 24013510 · NCT00967031 · Breast Neoplasms
  18. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.
    McCullough AE, Dell'orto P, Reinholz MM, et al. · Breast Cancer Res Treat · 2014 · Derived
    PubMed: PMID 24395109 · NCT00490139 (ALTTO) · Breast Neoplasms
  19. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M, Bonneterre J, Geyer CE, et al. · Eur J Cancer · 2014 · Derived
    PubMed: PMID 23953056 · NCT00777101 · Breast Neoplasms
  20. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Kurzrock R, Atkins J, Wheler J, et al. · Ann Oncol · 2014 · Derived
    PubMed: PMID 23676418 · NCT00495872
  21. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
    Inada-Inoue M, Ando Y, Kawada K, et al. · Cancer Chemother Pharmacol · 2014 · Derived
    PubMed: PMID 24464355 · NCT00516672 · Neoplasms
  22. Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling.
    Holmes FA, Espina V, Liotta LA, et al. · BMC Res Notes · 2014 · Derived
    PubMed: PMID 24304724 · NCT00524303 · Breast Neoplasms
  23. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
    Guarneri V, Generali DG, Frassoldati A, et al. · J Clin Oncol · 2014 · Derived
    PubMed: PMID 24590635 · NCT00429299 (CHERLOB) · Breast Neoplasms
  24. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.
    Fan M, Zhang J, Wang Z, et al. · Breast Cancer Res Treat · 2014 · Derived
    PubMed: PMID 24292957 · NCT01176669 · Breast Neoplasms
  25. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
    Falchook GS, Moulder SL, Wheler JJ, et al. · Ann Oncol · 2014 · Derived
    PubMed: PMID 24158411 · NCT00543504
  26. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Yoo C, Lee J, Rha SY, et al. · Invest New Drugs · 2014 · Background
    PubMed: PMID 24037083 · NCT02711007 · Neoplasm Metastasis
  27. Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study.
    Wang SN, Chuang SC, Lee KT, et al. · Hepatol Res · 2014 · Background
    PubMed: PMID 23672310 · NCT04521153 · Carcinoma, Hepatocellular
  28. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis.
    Tsuburaya A, Mizusawa J, Tanaka Y, et al. · Br J Surg · 2014 · Background
    PubMed: PMID 24668391 · NCT03229096 · Stomach Neoplasms
  29. Cancer statistics, 2014.
    Siegel R, Ma J, Zou Z, et al. · CA Cancer J Clin · 2014 · Background
    PubMed: PMID 24399786 · NCT02704767 · Lung Neoplasms
  30. Computed tomography characteristics of primary pulmonary lymphoepithelioma-like carcinoma in 41 patients.
    Ma H, Wu Y, Lin Y, et al. · Eur J Radiol · 2014 · Background
    PubMed: PMID 23465736 · NCT03709953 (Spark-AL003) · Lung Neoplasms
  31. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.
    Linch M, Miah AB, Thway K, et al. · Nat Rev Clin Oncol · 2014 · Background
    PubMed: PMID 24642677 · NCT02711007 · Neoplasm Metastasis
  32. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
    Kitayama J, Ishigami H, Yamaguchi H, et al. · Ann Surg Oncol · 2014 · Background
    PubMed: PMID 23975319 · NCT03007446 · Stomach Neoplasms
  33. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
    Hu X, Zhang J, Xu B, et al. · Int J Cancer · 2014 · Background
    PubMed: PMID 24604288 · NCT02704767 · Lung Neoplasms
  34. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB, Ciuleanu TE, Arrieta O, et al. · Lancet · 2014 · Background
    PubMed: PMID 24933332 · NCT03271255 · Colorectal Neoplasms
  35. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
    Fuchs CS, Tomasek J, Yong CJ, et al. · Lancet · 2014 · Background
    PubMed: PMID 24094768 · NCT03271255 · Colorectal Neoplasms
  36. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Früh M, De Ruysscher D, Popat S, et al. · Ann Oncol · 2014 · Background
    PubMed: PMID 23813929 · NCT02980809 · Small Cell Lung Carcinoma
  37. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Finn RS, Press MF, Dering J, et al. · Clin Cancer Res · 2014 · Background
    PubMed: PMID 24198242 · NCT00073528 · Breast Neoplasms
  38. An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
    Esteva FJ, Franco SX, Hagan MK, et al. · Oncologist · 2014 · Background
    PubMed: PMID 23697602 · NCT00272987 · Breast Neoplasms
  39. Adrenocortical carcinoma.
    Else T, Kim AC, Sabolch A, et al. · Endocr Rev · 2014 · Background
    PubMed: PMID 24423978 · NCT06831175 · Adrenal Gland Neoplasms
  40. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST).
    Ding Q, Cheng X, Yang L, et al. · J Thorac Dis · 2014 · Background
    PubMed: PMID 24976990 · NCT03104335 · Sarcoma
  41. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
    Conroy T, Galais MP, Raoul JL, et al. · Lancet Oncol · 2014 · Background
    PubMed: PMID 24556041 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  42. Second-line therapy in advanced biliary tract cancer: what should be the standard?
    Cereda S, Belli C, Rognone A, et al. · Crit Rev Oncol Hematol · 2014 · Background
    PubMed: PMID 23786845 · NCT03427242 · Biliary Tract Neoplasms
  43. Comprehensive molecular characterization of gastric adenocarcinoma.
    Cancer Genome Atlas Research Network · Nature · 2014 · Background
    PubMed: PMID 25079317 · NCT05029453 · Stomach Neoplasms
  44. Patients over 65 years are assigned lower ECOG PS scores than younger patients, although objectively measured physical activity is no different.
    Broderick JM, Hussey J, Kennedy MJ, et al. · J Geriatr Oncol · 2014 · Background
    PubMed: PMID 24484718 · NCT02711007 · Neoplasm Metastasis

2013 (27 papers)

  1. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
    Simonelli M, Zucali PA, Lorenzi E, et al. · Eur J Cancer · 2013 · Trial result
    PubMed: PMID 23146956 · NCT00984425
  2. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
    Okines AF, Langley RE, Thompson LC, et al. · Ann Oncol · 2013 · Trial result
    PubMed: PMID 23108952 · NCT00450203 (ST03)
  3. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
    Liu G, Chen YH, Kolesar J, et al. · Urol Oncol · 2013 · Trial result
    PubMed: PMID 21784672 · NCT00103194 · Prostatic Neoplasms
  4. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
    Li J, Qin S, Xu J, et al. · J Clin Oncol · 2013 · Trial result
    PubMed: PMID 23918952 · NCT03116555
  5. EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.
    Lalami Y, Specenier PM, Awada A, et al. · Radiother Oncol · 2013 · Trial result
    PubMed: PMID 22989664 · NCT00498953 · Head and Neck Neoplasms
  6. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
    Goss PE, Smith IE, O'Shaughnessy J, et al. · Lancet Oncol · 2013 · Trial result
    PubMed: PMID 23234763 · NCT03085368 · Breast Neoplasms
  7. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY, Oliner KS, Siena S, et al. · N Engl J Med · 2013 · Trial result
    PubMed: PMID 24024839 · NCT02829385 · Colorectal Neoplasms
  8. Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives.
    Custodio A, Barriuso J, de Castro J, et al. · Cancer Treat Rev · 2013 · Trial result
    PubMed: PMID 23510598 · NCT02829385 · Colorectal Neoplasms
  9. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
    Bonnefoi H, Zaman K, Debled M, et al. · Eur J Cancer · 2013 · Trial result
    PubMed: PMID 22999386 · NCT00450892 · Breast Neoplasms
  10. The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
    Stebbing J, Payne R, Reise J, et al. · PLoS One · 2013 · Derived
    PubMed: PMID 23667487 · NCT00820924 · Breast Neoplasms
  11. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
    Ro J, Park S, Kim S, et al. · BMC Cancer · 2013 · Derived
    PubMed: PMID 22839200 · NCT00338247 · Breast Neoplasms
  12. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
    Rimawi MF, Mayer IA, Forero A, et al. · J Clin Oncol · 2013 · Derived
    PubMed: PMID 23569315 · NCT00548184 · Breast Neoplasms
  13. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
    Guan Z, Xu B, DeSilvio ML, et al. · J Clin Oncol · 2013 · Derived
    PubMed: PMID 23509322 · NCT00281658 · Breast Neoplasms
  14. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
    Gadgeel SM, Lew DL, Synold TW, et al. · Cancer Chemother Pharmacol · 2013 · Derived
    PubMed: PMID 24057042 · NCT00352443 · Lymphoma, Large B-Cell, Diffuse
  15. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
    de Jonge MJ, Hamberg P, Verweij J, et al. · Invest New Drugs · 2013 · Derived
    PubMed: PMID 23054212 · NCT00430781 · Neoplasms
  16. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
    Bachelot T, Romieu G, Campone M, et al. · Lancet Oncol · 2013 · Derived
    PubMed: PMID 23122784 · NCT00967031 · Breast Neoplasms
  17. Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
    Yardley DA, Hart L, Bosserman L, et al. · Breast Cancer Res Treat · 2013 · Background
    PubMed: PMID 23224144 · NCT00709761 · Breast Neoplasms
  18. Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.
    Tenori L, Oakman C, Claudino WM, et al. · Mol Oncol · 2013 · Background
    PubMed: PMID 22687601 · NCT00075270 · Breast Neoplasms
  19. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A, Tang G, Rastogi P, et al. · Lancet Oncol · 2013 · Background
    PubMed: PMID 24095300 · NCT00486668
  20. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.
    Prat A, Parker JS, Fan C, et al. · Breast Cancer Res Treat · 2013 · Background
    PubMed: PMID 22752290 · NCT01973660 (PAMELA) · Breast Neoplasms
  21. Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma.
    Lammli J, Fan M, Rosenthal HG, et al. · Int Orthop · 2013 · Background
    PubMed: PMID 22855059 · NCT02711007 · Neoplasm Metastasis
  22. Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study.
    Kanda T, Yajima K, Kosugi S, et al. · Gastric Cancer · 2013 · Background
    PubMed: PMID 22033890 · NCT03007446 · Stomach Neoplasms
  23. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
    Johnston SR, Gómez H, Stemmer SM, et al. · Breast Cancer Res Treat · 2013 · Background
    PubMed: PMID 23283526 · NCT00347919 · Breast Neoplasms
  24. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210).
    Iwasaki Y, Sasako M, Yamamoto S, et al. · J Surg Oncol · 2013 · Background
    PubMed: PMID 23400787 · NCT03229096 · Stomach Neoplasms
  25. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
    Harrington K, Berrier A, Robinson M, et al. · Eur J Cancer · 2013 · Background
    PubMed: PMID 23265705 · NCT00387127 · Head and Neck Neoplasms
  26. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma.
    Bernthal NM, Federman N, Eilber FR, et al. · Cancer · 2013 · Background
    PubMed: PMID 22648705 · NCT02711007 · Neoplasm Metastasis
  27. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
    Bennouna J, Sastre J, Arnold D, et al. · Lancet Oncol · 2013 · Background
    PubMed: PMID 23168366 · NCT03271255 · Colorectal Neoplasms

2012 (31 papers)

  1. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells.
    Tong XZ, Wang F, Liang S, et al. · Biochem Pharmacol · 2012 · Trial result
    PubMed: PMID 22212563 · NCT03365765
  2. Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer.
    Monk BJ, Pandite LN · J Clin Oncol · 2012 · Trial result
    PubMed: PMID 22084371 · NCT00430781 · Neoplasms
  3. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
    Kaklamani VG, Siziopikou K, Scholtens D, et al. · Breast Cancer Res Treat · 2012 · Trial result
    PubMed: PMID 21359953 · NCT00331630 · Breast Neoplasms
  4. Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].
    Hamilton E, Blackwell K, Hobeika AC, et al. · J Transl Med · 2012 · Trial result
    PubMed: PMID 22325452 · NCT00952692 · Breast Neoplasms
  5. The ERBB network: at last, cancer therapy meets systems biology.
    Yarden Y, Pines G · Nat Rev Cancer · 2012 · Derived
    PubMed: PMID 22785351 · NCT00553358 (Neo ALTTO) · Breast Neoplasms
  6. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G, Eidtmann H, Rezai M, et al. · N Engl J Med · 2012 · Derived
    PubMed: PMID 22276820 · NCT00567554 (GeparQuinto) · Breast Neoplasms
  7. Trastuzumab emtansine for HER2-positive advanced breast cancer.
    Verma S, Miles D, Gianni L, et al. · N Engl J Med · 2012 · Derived
    PubMed: PMID 23020162 · NCT00829166 (EMILIA) · Breast Neoplasms
  8. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
    Untch M, Loibl S, Bischoff J, et al. · Lancet Oncol · 2012 · Derived
    PubMed: PMID 22257523 · NCT00567554 (GeparQuinto) · Breast Neoplasms
  9. Antibody therapy of cancer.
    Scott AM, Wolchok JD, Old LJ, et al. · Nat Rev Cancer · 2012 · Derived
    PubMed: PMID 22437872 · NCT00829166 (EMILIA) · Breast Neoplasms
  10. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.
    Pestrin M, Bessi S, Puglisi F, et al. · Breast Cancer Res Treat · 2012 · Derived
    PubMed: PMID 22476856 · NCT00820924 · Breast Neoplasms
  11. The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
    Labonte MJ, Wilson PM, Yang D, et al. · Ann Oncol · 2012 · Derived
    PubMed: PMID 21989330 · NCT00078572 · Breast Neoplasms
  12. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.
    Galsky MD, Von Hoff DD, Neubauer M, et al. · Invest New Drugs · 2012 · Derived
    PubMed: PMID 20857170 · NCT00447226 · Neoplasms
  13. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
    Baselga J, Bradbury I, Eidtmann H, et al. · Lancet · 2012 · Derived
    PubMed: PMID 22257673 · NCT00553358 (Neo ALTTO) · Breast Neoplasms
  14. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
    Xu BH, Jiang ZF, Chua D, et al. · Chin J Cancer · 2012 · Background
    PubMed: PMID 21527065 · NCT00508274 · Breast Neoplasms
  15. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.
    Wu Y, Amonkar MM, Sherrill BH, et al. · Ann Oncol · 2012 · Background
    PubMed: PMID 21406472 · NCT00320385 · Breast Neoplasms
  16. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.
    Wang YC, Morrison G, Gillihan R, et al. · Breast Cancer Res · 2012 · Background
    PubMed: PMID 22123186 · NCT02238509 · Breast Neoplasms
  17. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
    van der Graaf WT, Blay JY, Chawla SP, et al. · Lancet · 2012 · Background
    PubMed: PMID 22595799 · NCT03104335 · Sarcoma
  18. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Van Cutsem E, Tabernero J, Lakomy R, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22949147 · NCT03271255 · Colorectal Neoplasms
  19. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
    Scagliotti GV, Krzakowski M, Szczesna A, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22564989 · NCT02704767 · Lung Neoplasms
  20. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.
    Rugo HS, Chien AJ, Franco SX, et al. · Breast Cancer Res Treat · 2012 · Background
    PubMed: PMID 22198412 · NCT00444535 · Breast Neoplasms
  21. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.
    Peck J, Wei L, Zalupski M, et al. · Oncology · 2012 · Background
    PubMed: PMID 22433475 · NCT00107536 · Carcinoma, Hepatocellular
  22. MicroRNA expression characterizes oligometastasis(es).
    Lussier YA, Xing HR, Salama JK, et al. · PLoS One · 2012 · Background
    PubMed: PMID 22174856 · NCT03457467 · Breast Neoplasms
  23. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
    Lin NU, Eierman W, Greil R, et al. · J Neurooncol · 2012 · Background
    PubMed: PMID 21706359 · NCT00437073 · Breast Neoplasms
  24. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer.
    Inoue K, Nakane Y, Kogire M, et al. · Eur J Surg Oncol · 2012 · Background
    PubMed: PMID 22154885 · NCT03007446 · Stomach Neoplasms
  25. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
    Guarneri V, Frassoldati A, Bottini A, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22493419 · NCT00429299 (CHERLOB) · Breast Neoplasms
  26. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
    Grignani G, Palmerini E, Dileo P, et al. · Ann Oncol · 2012 · Background
    PubMed: PMID 21527590 · NCT02711007 · Neoplasm Metastasis
  27. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L, Pienkowski T, Im YH, et al. · Lancet Oncol · 2012 · Background
    PubMed: PMID 22153890 · NCT01973660 (PAMELA) · Breast Neoplasms
  28. Combination chemotherapy in advanced adrenocortical carcinoma.
    Fassnacht M, Terzolo M, Allolio B, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22551107 · NCT06831175 · Adrenal Gland Neoplasms
  29. Comprehensive molecular portraits of human breast tumours.
    Cancer Genome Atlas Network · Nature · 2012 · Background
    PubMed: PMID 23000897 · NCT01973660 (PAMELA) · Breast Neoplasms
  30. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
    Burris HA, Dowlati A, Moss RA, et al. · Mol Cancer Ther · 2012 · Background
    PubMed: PMID 22679111 · NCT00388076 · Breast Neoplasms
  31. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
    Blackwell KL, Burstein HJ, Storniolo AM, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22689807 · NCT00320385 · Breast Neoplasms

2011 (25 papers)

  1. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.
    Tian S, Quan H, Xie C, et al. · Cancer Sci · 2011 · Trial result
    PubMed: PMID 21443688 · NCT03365765
  2. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Thuss-Patience PC, Kretzschmar A, Bichev D, et al. · Eur J Cancer · 2011 · Trial result
    PubMed: PMID 21742485 · NCT04286711
  3. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies.
    Li J, Zhao X, Chen L, et al. · BMC Cancer · 2011 · Trial result
    PubMed: PMID 20923544 · NCT03201146 · Carcinoma, Non-Small-Cell Lung
  4. Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland.
    Le Tourneau C, Razak AR, Levy C, et al. · Br J Ophthalmol · 2011 · Trial result
    PubMed: PMID 21183517 · NCT02989259 · Head and Neck Neoplasms
  5. Global cancer statistics.
    Jemal A, Bray F, Center MM, et al. · CA Cancer J Clin · 2011 · Trial result
    PubMed: PMID 21296855 · NCT03116555
  6. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
    Cameron D, Casey M, Oliva C, et al. · Oncologist · 2011 · Trial result
    PubMed: PMID 20736298 · NCT00078572 · Breast Neoplasms
  7. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.
    Wang L, Zhang Q, Zhang J, et al. · BMC Cancer · 2011 · Derived
    PubMed: PMID 21676217 · NCT00338247 · Breast Neoplasms
  8. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
    Dennie TW, Fleming RA, Bowen CJ, et al. · Clin Colorectal Cancer · 2011 · Derived
    PubMed: PMID 21609937 · NCT00536809 · Colorectal Neoplasms
  9. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
    Zhou C, Wu YL, Chen G, et al. · Lancet Oncol · 2011 · Background
    PubMed: PMID 21783417 · NCT02704767 · Lung Neoplasms
  10. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
    von Minckwitz G, Schwedler K, Schmidt M, et al. · Eur J Cancer · 2011 · Background
    PubMed: PMID 21741829 · NCT02238509 · Breast Neoplasms
  11. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
    Villanueva C, Awada A, Campone M, et al. · Eur J Cancer · 2011 · Background
    PubMed: PMID 21339064 · NCT01934894
  12. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.
    Tan AR, Dowlati A, Jones SF, et al. · Oncologist · 2011 · Background
    PubMed: PMID 21147873 · NCT00388076 · Breast Neoplasms
  13. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR, Burris HA, Greco FA, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21576636 · NCT02704767 · Lung Neoplasms
  14. Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.
    Sherrill B, Amonkar MM, Sherif B, et al. · Oncologist · 2011 · Background
    PubMed: PMID 20798196 · NCT00073528 · Breast Neoplasms
  15. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ, Diéras V, Glaspy J, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21383283 · NCT02878057 · Breast Neoplasms
  16. Detection of HER2 amplification in circulating free DNA in patients with breast cancer.
    Page K, Hava N, Ward B, et al. · Br J Cancer · 2011 · Background
    PubMed: PMID 21427727 · NCT02238509 · Breast Neoplasms
  17. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.
    Omata M, Lesmana LA, Tateishi R, et al. · Hepatol Int · 2011 · Background
    PubMed: PMID 20827404 · NCT03261791 · Carcinoma, Hepatocellular
  18. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
    Ohtsu A, Shah MA, Van Cutsem E, et al. · J Clin Oncol · 2011 · Background
    PubMed: PMID 21844504 · NCT03007446 · Stomach Neoplasms
  19. Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.
    Lipton A, Leitzel K, Ali SM, et al. · Cancer · 2011 · Background
    PubMed: PMID 21456017 · NCT00089999 · Breast Neoplasms
  20. A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
    Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N, et al. · Oncology · 2011 · Background
    PubMed: PMID 21088439 · NCT02238509 · Breast Neoplasms
  21. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
    Fehm T, Müller V, Aktas B, et al. · Breast Cancer Res Treat · 2011 · Background
    PubMed: PMID 20859679 · NCT01619111 (DETECT III) · Breast Neoplasms
  22. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion.
    Elson-Schwab I, Lorentzen A, Marshall CJ, et al. · PLoS One · 2011 · Background
    PubMed: PMID 20957176 · NCT03457467 · Breast Neoplasms
  23. Changing end points in breast-cancer drug approval--the Avastin story.
    D'Agostino RB · N Engl J Med · 2011 · Background
    PubMed: PMID 21707384 · NCT02878057 · Breast Neoplasms
  24. Trastuzumab single-drug therapy after failure of cytotoxic treatment for metastatic breast cancer.
    Clemens M, Eidtmann H, Nitz U, et al. · Onkologie · 2011 · Background
    PubMed: PMID 20838057 · NCT02238509 · Breast Neoplasms
  25. Chemoradiation therapy in nonsmall cell lung cancer.
    Baas P, Belderbos JS, van den Heuvel M, et al. · Curr Opin Oncol · 2011 · Background
    PubMed: PMID 21178617 · NCT02704767 · Lung Neoplasms

2010 (25 papers)

  1. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
    Valle J, Wasan H, Palmer DH, et al. · N Engl J Med · 2010 · Trial result
    PubMed: PMID 20375404 · NCT04642664 (ACABC) · Cholangiocarcinoma
  2. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
    Sutherland S, Ashley S, Miles D, et al. · Br J Cancer · 2010 · Trial result
    PubMed: PMID 20179708 · NCT00263588 · Breast Neoplasms
  3. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
    Monk BJ, Mas Lopez L, Zarba JJ, et al. · J Clin Oncol · 2010 · Trial result
    PubMed: PMID 20606083 · NCT00430781 · Neoplasms
  4. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters.
    Mi YJ, Liang YJ, Huang HB, et al. · Cancer Res · 2010 · Trial result
    PubMed: PMID 20876799 · NCT03365765
  5. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
    Kerkar SP, Kemp CD, Duffy A, et al. · Trials · 2010 · Trial result
    PubMed: PMID 20030854 · NCT01264081 · Melanoma
  6. Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer.
    Kaufman B, Wu Y, Amonkar MM, et al. · Curr Med Res Opin · 2010 · Trial result
    PubMed: PMID 20214527 · NCT00105950 · Breast Neoplasms
  7. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
    Dang C, Lin N, Moy B, et al. · J Clin Oncol · 2010 · Trial result
    PubMed: PMID 20479410 · NCT00482391 · Breast Neoplasms
  8. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
    Bekaii-Saab T, Markowitz J, Prescott N, et al. · Clin Cancer Res · 2010 · Trial result
    PubMed: PMID 19737952 · NCT00107536 · Carcinoma, Hepatocellular
  9. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.
    Sherrill B, Di Leo A, Amonkar MM, et al. · Curr Med Res Opin · 2010 · Derived
    PubMed: PMID 20095796 · NCT00075270 · Breast Neoplasms
  10. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
    Valachis A, Polyzos NP, Patsopoulos NA, et al. · Breast Cancer Res Treat · 2010 · Background
    PubMed: PMID 20063120 · NCT02878057 · Breast Neoplasms
  11. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.
    Songun I, Putter H, Kranenbarg EM, et al. · Lancet Oncol · 2010 · Background
    PubMed: PMID 20409751 · NCT03229096 · Stomach Neoplasms
  12. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
    Schwartzberg LS, Franco SX, Florance A, et al. · Oncologist · 2010 · Background
    PubMed: PMID 20156908 · NCT00073528 · Breast Neoplasms
  13. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
    Ross HJ, Blumenschein GR, Aisner J, et al. · Clin Cancer Res · 2010 · Background
    PubMed: PMID 20215545 · NCT00073008 · Neoplasm Metastasis
  14. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Miles DW, Chan A, Dirix LY, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20498403 · NCT02878057 · Breast Neoplasms
  15. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
    McNall-Knapp RY, Williams CN, Reeves EN, et al. · Pediatr Blood Cancer · 2010 · Background
    PubMed: PMID 20405511 · NCT02711007 · Neoplasm Metastasis
  16. Stereotactic body radiation therapy: a novel treatment modality.
    Lo SS, Fakiris AJ, Chang EL, et al. · Nat Rev Clin Oncol · 2010 · Background
    PubMed: PMID 19997074 · NCT03457467 · Breast Neoplasms
  17. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S, Pippen J, Pivot X, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 19786658 · NCT00073528 · Breast Neoplasms
  18. miR-200 enhances mouse breast cancer cell colonization to form distant metastases.
    Dykxhoorn DM, Wu Y, Xie H, et al. · PLoS One · 2010 · Background
    PubMed: PMID 19787069 · NCT03457467 · Breast Neoplasms
  19. Analysis of the genome to personalize therapy for melanoma.
    Davies MA, Samuels Y · Oncogene · 2010 · Background
    PubMed: PMID 20697348 · NCT01264081 · Melanoma
  20. Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.
    Cirillo M, Venturini M, Ciccarelli L, et al. · Ann Oncol · 2010 · Background
    PubMed: PMID 19622510 · NCT03104335 · Sarcoma
  21. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.
    Boussen H, Cristofanilli M, Zaks T, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20530274 · NCT00111787 · Breast Neoplasms
  22. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.
    Blackwell KL, Burstein HJ, Storniolo AM, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20124187 · NCT01273610 · Breast Neoplasms
  23. Osteosarcoma: the COSS experience.
    Bielack S, Jürgens H, Jundt G, et al. · Cancer Treat Res · 2010 · Background
    PubMed: PMID 20213397 · NCT02711007 · Neoplasm Metastasis
  24. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Bang YJ, Van Cutsem E, Feyereislova A, et al. · Lancet · 2010 · Background
    PubMed: PMID 20728210 · NCT03229096 · Stomach Neoplasms
  25. Human papillomavirus and survival of patients with oropharyngeal cancer.
    Ang KK, Harris J, Wheeler R, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20530316 · NCT01711658 (TRYHARD) · Head and Neck Neoplasms

2009 (18 papers)

  1. Outpatient chemotherapy with S-1 for recurrent head and neck cancer.
    Yamashita T, Shinden S, Watabe T, et al. · Anticancer Res · 2009 · Trial result
    PubMed: PMID 19331206 · NCT02943252 · Head and Neck Neoplasms
  2. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
    Kaufman B, Trudeau M, Awada A, et al. · Lancet Oncol · 2009 · Trial result
    PubMed: PMID 19394894 · NCT00105950 · Breast Neoplasms
  3. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
    Chien AJ, Illi JA, Ko AH, et al. · Clin Cancer Res · 2009 · Trial result
    PubMed: PMID 19706807 · NCT00313599 · Breast Neoplasms
  4. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
    Cameron D, Casey M, Press M, et al. · Breast Cancer Res Treat · 2009 · Trial result
    PubMed: PMID 18188694 · NCT00078572 · Breast Neoplasms
  5. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer.
    Yoshikawa T, Sasako M, Yamamoto S, et al. · Br J Surg · 2009 · Background
    PubMed: PMID 19644974 · NCT03229096 · Stomach Neoplasms
  6. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.
    Toi M, Iwata H, Fujiwara Y, et al. · Br J Cancer · 2009 · Background
    PubMed: PMID 19844234 · NCT00320411 · Breast Neoplasms
  7. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
    Sleijfer S, Ray-Coquard I, Papai Z, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19451427 · NCT02711007 · Neoplasm Metastasis
  8. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
    Prickett TD, Agrawal NS, Wei X, et al. · Nat Genet · 2009 · Background
    PubMed: PMID 19718025 · NCT01264081 · Melanoma
  9. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
    Mok TS, Wu YL, Thongprasert S, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19692680 · NCT02704767 · Lung Neoplasms
  10. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy.
    Milano MT, Zhang H, Metcalfe SK, et al. · Breast Cancer Res Treat · 2009 · Background
    PubMed: PMID 18719992 · NCT03457467 · Breast Neoplasms
  11. Stereotactic body radiation therapy for oligometastases.
    Lo SS, Fakiris AJ, Teh BS, et al. · Expert Rev Anticancer Ther · 2009 · Background
    PubMed: PMID 19445579 · NCT03457467 · Breast Neoplasms
  12. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
    Lin NU, Diéras V, Paul D, et al. · Clin Cancer Res · 2009 · Background
    PubMed: PMID 19228746 · NCT01934894
  13. Synthetic lethality--a new direction in cancer-drug development.
    Iglehart JD, Silver DP · N Engl J Med · 2009 · Background
    PubMed: PMID 19553640 · NCT07371910 · Breast Neoplasms
  14. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
    Finn RS, Press MF, Dering J, et al. · J Clin Oncol · 2009 · Background
    PubMed: PMID 19620495 · NCT00075270 · Breast Neoplasms
  15. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas.
    Everhart JE, Ruhl CE · Gastroenterology · 2009 · Background
    PubMed: PMID 19245868 · NCT04720131 · Biliary Tract Neoplasms
  16. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Background
    PubMed: PMID 19097774 · NCT01934894
  17. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N, Yamamoto S, Fukuda H, et al. · Lancet Oncol · 2009 · Background
    PubMed: PMID 19818685 · NCT03229096 · Stomach Neoplasms
  18. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients.
    Berger M, Grignani G, Ferrari S, et al. · Cancer · 2009 · Background
    PubMed: PMID 19452540 · NCT02711007 · Neoplasm Metastasis

2008 (12 papers)

  1. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
    Kimball KJ, Numnum TM, Kirby TO, et al. · Gynecol Oncol · 2008 · Trial result
    PubMed: PMID 18692224 · NCT00317434 · Ovarian Neoplasms
  2. Capecitabine and oxaliplatin for advanced esophagogastric cancer.
    Cunningham D, Starling N, Rao S, et al. · N Engl J Med · 2008 · Trial result
    PubMed: PMID 18172173 · NCT04286711
  3. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
    Catalano V, Graziano F, Santini D, et al. · Br J Cancer · 2008 · Trial result
    PubMed: PMID 18971936 · NCT03116555
  4. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
    Alberts DS, Liu PY, Wilczynski SP, et al. · Gynecol Oncol · 2008 · Trial result
    PubMed: PMID 17949799 · NCT03587129 · Ovarian Neoplasms
  5. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.
    Sasako M, Sano T, Yamamoto S, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18669424 · NCT03229096 · Stomach Neoplasms
  6. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.
    Pivot X, Koralewski P, Hidalgo JL, et al. · Ann Oncol · 2008 · Background
    PubMed: PMID 18436520 · NCT01934894
  7. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
    Navid F, Willert JR, McCarville MB, et al. · Cancer · 2008 · Background
    PubMed: PMID 18484657 · NCT02711007 · Neoplasm Metastasis
  8. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
    Miller K, Wang M, Gralow J, et al. · N Engl J Med · 2008 · Background
    PubMed: PMID 18160686 · NCT02878057 · Breast Neoplasms
  9. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
    Lin NU, Carey LA, Liu MC, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18421051 · NCT01934894
  10. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W, Narahara H, Hara T, et al. · Lancet Oncol · 2008 · Background
    PubMed: PMID 18282805 · NCT03229096 · Stomach Neoplasms
  11. Cancer statistics, 2008.
    Jemal A, Siegel R, Ward E, et al. · CA Cancer J Clin · 2008 · Background
    PubMed: PMID 18287387 · NCT02878057 · Breast Neoplasms
  12. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
    Adjei AA, Cohen RB, Franklin W, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18390968 · NCT01306045 · Carcinoma, Non-Small-Cell Lung

2007 (10 papers)

  1. Ovarian cancer.
    Colombo N, Van Gorp T, Parma G, et al. · Crit Rev Oncol Hematol · 2007 · Trial result
    PubMed: PMID 17018256 · NCT03587129 · Ovarian Neoplasms
  2. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma.
    Wagner LM, McAllister N, Goldsby RE, et al. · Pediatr Blood Cancer · 2007 · Background
    PubMed: PMID 16317751 · NCT07479732 · Osteosarcoma
  3. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 17978289 · NCT04338438 · Stomach Neoplasms
  4. Trimodality treatment and selective organ preservation for bladder cancer.
    Rödel C, Weiss C, Sauer R, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17158539 · NCT01245660 (LAPAINBLAD) · Urinary Bladder Neoplasms
  5. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
    Perey L, Paridaens R, Hawle H, et al. · Ann Oncol · 2007 · Background
    PubMed: PMID 17030543 · NCT02394496 (OVER) · Breast Neoplasms
  6. Brain metastases: the HER2 paradigm.
    Lin NU, Winer EP · Clin Cancer Res · 2007 · Background
    PubMed: PMID 17363517 · NCT01934894
  7. Pharmacokinetics of chemotherapy in the older patient.
    Hurria A, Lichtman SM · Cancer Control · 2007 · Background
    PubMed: PMID 17242669 · NCT01273610 · Breast Neoplasms
  8. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
    Geyer CE, Forster J, Lindquist D, et al. · N Engl J Med · 2007 · Background
    PubMed: PMID 17192538 · NCT02238509 · Breast Neoplasms
  9. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
    Eckardt JR, von Pawel J, Pujol JL, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17513814 · NCT02980809 · Small Cell Lung Carcinoma
  10. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
    Bomgaars LR, Bernstein M, Krailo M, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17925558 · NCT02711007 · Neoplasm Metastasis

2006 (9 papers)

  1. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
    Kyrgiou M, Salanti G, Pavlidis N, et al. · J Natl Cancer Inst · 2006 · Trial result
    PubMed: PMID 17105988 · NCT03587129 · Ovarian Neoplasms
  2. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
    O'Brien ME, Ciuleanu TE, Tsekov H, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 17135646 · NCT02980809 · Small Cell Lung Carcinoma
  3. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R, Yu D, Hung MC, et al. · Nat Clin Pract Oncol · 2006 · Background
    PubMed: PMID 16683005 · NCT02238509 · Breast Neoplasms
  4. Herceptin: mechanisms of action and resistance.
    Nahta R, Esteva FJ · Cancer Lett · 2006 · Background
    PubMed: PMID 16458110 · NCT02238509 · Breast Neoplasms
  5. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
    Ingle JN, Suman VJ, Rowland KM, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16505423 · NCT02394496 (OVER) · Breast Neoplasms
  6. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
    Debiec-Rychter M, Sciot R, Le Cesne A, et al. · Eur J Cancer · 2006 · Background
    PubMed: PMID 16624552 · NCT02711007 · Neoplasm Metastasis
  7. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    Cunningham D, Allum WH, Stenning SP, et al. · N Engl J Med · 2006 · Background
    PubMed: PMID 16822992 · NCT03229096 · Stomach Neoplasms
  8. Clinical review: Adrenocortical carcinoma: clinical update.
    Allolio B, Fassnacht M · J Clin Endocrinol Metab · 2006 · Background
    PubMed: PMID 16551738 · NCT06831175 · Adrenal Gland Neoplasms
  9. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.
    Abiven G, Coste J, Groussin L, et al. · J Clin Endocrinol Metab · 2006 · Background
    PubMed: PMID 16670169 · NCT06831175 · Adrenal Gland Neoplasms

2005 (16 papers)

  1. Ovarian cancer metastasis: integrating insights from disparate model organisms.
    Naora H, Montell DJ · Nat Rev Cancer · 2005 · Trial result
    PubMed: PMID 15864277 · NCT03587129 · Ovarian Neoplasms
  2. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E, Yothers G, Romond E, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 16258083 · NCT02238509 · Breast Neoplasms
  3. Erlotinib in previously treated non-small-cell lung cancer.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 16014882 · NCT02711007 · Neoplasm Metastasis
  4. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.
    Santen RJ, Song RX, Zhang Z, et al. · J Steroid Biochem Mol Biol · 2005 · Background
    PubMed: PMID 16024245 · NCT02394496 (OVER) · Breast Neoplasms
  5. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
    Romond EH, Perez EA, Bryant J, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 16236738 · NCT02238509 · Breast Neoplasms
  6. Tumor vaccine against recurrence of hepatocellular carcinoma.
    Peng BG, Liang LJ, He Q, et al. · World J Gastroenterol · 2005 · Background
    PubMed: PMID 15655825 · NCT04521153 · Carcinoma, Hepatocellular
  7. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS).
    Kempf-Bielack B, Bielack SS, Jürgens H, et al. · J Clin Oncol · 2005 · Background
    PubMed: PMID 15659502 · NCT02711007 · Neoplasm Metastasis
  8. Developing a cancer-specific geriatric assessment: a feasibility study.
    Hurria A, Gupta S, Zauderer M, et al. · Cancer · 2005 · Background
    PubMed: PMID 16206252 · NCT01273610 · Breast Neoplasms
  9. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A, Cuzick J, Baum M, et al. · Lancet · 2005 · Background
    PubMed: PMID 15639680 · NCT02394496 (OVER) · Breast Neoplasms
  10. Current and future perspectives on fulvestrant.
    Gradishar WJ, Sahmoud T · Clin Breast Cancer · 2005 · Background
    PubMed: PMID 15865847 · NCT02394496 (OVER) · Breast Neoplasms
  11. Somatic mutations of the protein kinase gene family in human lung cancer.
    Davies H, Hunter C, Smith R, et al. · Cancer Res · 2005 · Background
    PubMed: PMID 16140923 · NCT03725423
  12. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ · N Engl J Med · 2005 · Background
    PubMed: PMID 16236735 · NCT02394496 (OVER) · Breast Neoplasms
  13. Aromatase inhibitors in the treatment of breast cancer.
    Brueggemeier RW, Hackett JC, Diaz-Cruz ES, et al. · Endocr Rev · 2005 · Background
    PubMed: PMID 15814851 · NCT02394496 (OVER) · Breast Neoplasms
  14. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.
    Berruti A, Terzolo M, Sperone P, et al. · Endocr Relat Cancer · 2005 · Background
    PubMed: PMID 16172198 · NCT06831175 · Adrenal Gland Neoplasms
  15. Perturbations of the AKT signaling pathway in human cancer.
    Altomare DA, Testa JR · Oncogene · 2005 · Background
    PubMed: PMID 16288292 · NCT01306045 · Carcinoma, Non-Small-Cell Lung
  16. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.
    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration · Eur Urol · 2005 · Background
    PubMed: PMID 15939524 · NCT01245660 (LAPAINBLAD) · Urinary Bladder Neoplasms

2004 (11 papers)

  1. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
    Willett CG, Boucher Y, di Tomaso E, et al. · Nat Med · 2004 · Trial result
    PubMed: PMID 14745444 · NCT03365765
  2. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.
    Xia W, Liu LH, Ho P, et al. · Oncogene · 2004 · Background
    PubMed: PMID 14737100 · NCT02394496 (OVER) · Breast Neoplasms
  3. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.
    Talarico L, Chen G, Pazdur R, et al. · J Clin Oncol · 2004 · Background
    PubMed: PMID 15542812 · NCT01273610 · Breast Neoplasms
  4. Clinical role of circulating Epstein-Barr virus DNA as a tumor marker in lymphoepithelioma-like carcinoma of the lung.
    Ngan RK, Yip TT, Cheng WW, et al. · Ann N Y Acad Sci · 2004 · Background
    PubMed: PMID 15251971 · NCT03709953 (Spark-AL003) · Lung Neoplasms
  5. Biological rationale for endocrine therapy in breast cancer.
    Miller WR · Best Pract Res Clin Endocrinol Metab · 2004 · Background
    PubMed: PMID 14687595 · NCT02394496 (OVER) · Breast Neoplasms
  6. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma.
    Kuang M, Peng BG, Lu MD, et al. · Clin Cancer Res · 2004 · Background
    PubMed: PMID 15014006 · NCT04521153 · Carcinoma, Hepatocellular
  7. Aromatase inhibitors for breast cancer: lessons from the laboratory.
    Johnston SR, Dowsett M · Nat Rev Cancer · 2004 · Background
    PubMed: PMID 14668813 · NCT02394496 (OVER) · Breast Neoplasms
  8. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.
    Grossi PM, Ochiai H, Archer GE, et al. · Clin Cancer Res · 2004 · Background
    PubMed: PMID 14654531 · NCT02394496 (OVER) · Breast Neoplasms
  9. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
    Coombes RC, Hall E, Gibson LJ, et al. · N Engl J Med · 2004 · Background
    PubMed: PMID 15014181 · NCT02394496 (OVER) · Breast Neoplasms
  10. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.
    Clayton AJ, Danson S, Jolly S, et al. · Br J Cancer · 2004 · Background
    PubMed: PMID 15266327 · NCT02394496 (OVER) · Breast Neoplasms
  11. Surgical management and outcome of metachronous Krukenberg tumors from gastric cancer.
    Cheong JH, Hyung WJ, Chen J, et al. · J Surg Oncol · 2004 · Background
    PubMed: PMID 15221918 · NCT02711007 · Neoplasm Metastasis

2003 (13 papers)

  1. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
    Parmar MK, Ledermann JA, Colombo N, et al. · Lancet · 2003 · Trial result
    PubMed: PMID 12826431 · NCT03587129 · Ovarian Neoplasms
  2. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    Rusnak DW, Lackey K, Affleck K, et al. · Mol Cancer Ther · 2003 · Background
    PubMed: PMID 12467226 · NCT02394496 (OVER) · Breast Neoplasms
  3. Computed tomography characteristics of advanced primary pulmonary lymphoepithelioma-like carcinoma.
    Ooi GC, Ho JC, Khong PL, et al. · Eur Radiol · 2003 · Background
    PubMed: PMID 12594554 · NCT03709953 (Spark-AL003) · Lung Neoplasms
  4. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
    Mauriac L, Pippen JE, Quaresma Albano J, et al. · Eur J Cancer · 2003 · Background
    PubMed: PMID 12763210 · NCT02394496 (OVER) · Breast Neoplasms
  5. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.
    Martin LA, Farmer I, Johnston SR, et al. · J Biol Chem · 2003 · Background
    PubMed: PMID 12775708 · NCT02394496 (OVER) · Breast Neoplasms
  6. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
    Holbro T, Beerli RR, Maurer F, et al. · Proc Natl Acad Sci U S A · 2003 · Background
    PubMed: PMID 12853564 · NCT02394496 (OVER) · Breast Neoplasms
  7. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels.
    Hendriks BS, Opresko LK, Wiley HS, et al. · J Biol Chem · 2003 · Background
    PubMed: PMID 12686539 · NCT00107003 · Neoplasms
  8. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    Goss PE, Ingle JN, Martino S, et al. · N Engl J Med · 2003 · Background
    PubMed: PMID 14551341 · NCT02394496 (OVER) · Breast Neoplasms
  9. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.
    Cisternino S, Bourasset F, Archimbaud Y, et al. · Br J Pharmacol · 2003 · Background
    PubMed: PMID 12711638 · NCT01934894
  10. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.
    Burgess AW, Cho HS, Eigenbrot C, et al. · Mol Cell · 2003 · Background
    PubMed: PMID 14527402 · NCT00107003 · Neoplasms
  11. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
    Bendell JC, Domchek SM, Burstein HJ, et al. · Cancer · 2003 · Background
    PubMed: PMID 12784331 · NCT02394496 (OVER) · Breast Neoplasms
  12. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).
    Allen LF, Sebolt-Leopold J, Meyer MB, et al. · Semin Oncol · 2003 · Background
    PubMed: PMID 14613031 · NCT01306045 · Carcinoma, Non-Small-Cell Lung
  13. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers.
    Addo S, Yates RA, Laight A, et al. · Br J Cancer · 2003 · Background
    PubMed: PMID 12454761 · NCT02394496 (OVER) · Breast Neoplasms

2002 (13 papers)

  1. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W, Mullin RJ, Keith BR, et al. · Oncogene · 2002 · Background
    PubMed: PMID 12214266 · NCT02394496 (OVER) · Breast Neoplasms
  2. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
    Vogel CL, Cobleigh MA, Tripathy D, et al. · J Clin Oncol · 2002 · Background
    PubMed: PMID 11821453 · NCT02394496 (OVER) · Breast Neoplasms
  3. Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery.
    Thompson RC, Cheng EY, Clohisy DR, et al. · Clin Orthop Relat Res · 2002 · Background
    PubMed: PMID 11953615 · NCT02711007 · Neoplasm Metastasis
  4. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Osborne CK, Pippen J, Jones SE, et al. · J Clin Oncol · 2002 · Background
    PubMed: PMID 12177098 · NCT02394496 (OVER) · Breast Neoplasms
  5. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.
    Minsky BD, Pajak TF, Ginsberg RJ, et al. · J Clin Oncol · 2002 · Background
    PubMed: PMID 11870157 · NCT06281886 · Esophageal Squamous Cell Carcinoma
  6. HER2/neu in the management of invasive breast cancer.
    Meric F, Hung MC, Hortobagyi GN, et al. · J Am Coll Surg · 2002 · Background
    PubMed: PMID 11949754 · NCT02394496 (OVER) · Breast Neoplasms
  7. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
    Lu Y, Zi X, Zhao Y, et al. · J Natl Cancer Inst · 2002 · Background
    PubMed: PMID 11752009 · NCT02394496 (OVER) · Breast Neoplasms
  8. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Howell A, Robertson JF, Quaresma Albano J, et al. · J Clin Oncol · 2002 · Background
    PubMed: PMID 12177099 · NCT02394496 (OVER) · Breast Neoplasms
  9. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism.
    Gerber HP, Malik AK, Solar GP, et al. · Nature · 2002 · Background
    PubMed: PMID 12087404 · NCT02394496 (OVER) · Breast Neoplasms
  10. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
    Cosetti M, Wexler LH, Calleja E, et al. · J Pediatr Hematol Oncol · 2002 · Background
    PubMed: PMID 11990694 · NCT02711007 · Neoplasm Metastasis
  11. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
    Choe G, Park JK, Jouben-Steele L, et al. · Clin Cancer Res · 2002 · Background
    PubMed: PMID 12231534 · NCT00107003 · Neoplasms
  12. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
    Chan CM, Martin LA, Johnston SR, et al. · J Steroid Biochem Mol Biol · 2002 · Background
    PubMed: PMID 12361723 · NCT02394496 (OVER) · Breast Neoplasms
  13. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
    Bonneterre J, Buzdar A, Nabholtz JM, et al. · Cancer · 2002 · Background
    PubMed: PMID 11745278 · NCT02394496 (OVER) · Breast Neoplasms

2001 (15 papers)

  1. Untangling the ErbB signalling network.
    Yarden Y, Sliwkowski MX · Nat Rev Mol Cell Biol · 2001 · Background
    PubMed: PMID 11252954 · NCT02394496 (OVER) · Breast Neoplasms
  2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    Slamon DJ, Leyland-Jones B, Shak S, et al. · N Engl J Med · 2001 · Background
    PubMed: PMID 11248153 · NCT02394496 (OVER) · Breast Neoplasms
  3. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
    Saylors RL, Stine KC, Sullivan J, et al. · J Clin Oncol · 2001 · Background
    PubMed: PMID 11481351 · NCT02711007 · Neoplasm Metastasis
  4. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW, Affleck K, Cockerill SG, et al. · Cancer Res · 2001 · Background
    PubMed: PMID 11585755 · NCT02394496 (OVER) · Breast Neoplasms
  5. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
    Robertson JF, Nicholson RI, Bundred NJ, et al. · Cancer Res · 2001 · Background
    PubMed: PMID 11559545 · NCT02394496 (OVER) · Breast Neoplasms
  6. EGFR and cancer prognosis.
    Nicholson RI, Gee JM, Harper ME, et al. · Eur J Cancer · 2001 · Background
    PubMed: PMID 11597399 · NCT02394496 (OVER) · Breast Neoplasms
  7. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
    Mouridsen H, Gershanovich M, Sun Y, et al. · J Clin Oncol · 2001 · Background
    PubMed: PMID 11352951 · NCT02394496 (OVER) · Breast Neoplasms
  8. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).
    McClelland RA, Barrow D, Madden TA, et al. · Endocrinology · 2001 · Background
    PubMed: PMID 11415996 · NCT02394496 (OVER) · Breast Neoplasms
  9. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors.
    Jimenez RE, Hussain M, Bianco FJ, et al. · Clin Cancer Res · 2001 · Background
    PubMed: PMID 11489824 · NCT01245660 (LAPAINBLAD) · Urinary Bladder Neoplasms
  10. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.
    Icard P, Goudet P, Charpenay C, et al. · World J Surg · 2001 · Background
    PubMed: PMID 11572030 · NCT06831175 · Adrenal Gland Neoplasms
  11. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.
    Fisher B, Anderson S, Tan-Chiu E, et al. · J Clin Oncol · 2001 · Background
    PubMed: PMID 11181655 · NCT02394496 (OVER) · Breast Neoplasms
  12. Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2.
    Cockerill S, Stubberfield C, Stables J, et al. · Bioorg Med Chem Lett · 2001 · Background
    PubMed: PMID 11378364 · NCT02394496 (OVER) · Breast Neoplasms
  13. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
    Buzdar A, Douma J, Davidson N, et al. · J Clin Oncol · 2001 · Background
    PubMed: PMID 11454883 · NCT02394496 (OVER) · Breast Neoplasms
  14. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
    Burstein HJ, Kuter I, Campos SM, et al. · J Clin Oncol · 2001 · Background
    PubMed: PMID 11352965 · NCT02394496 (OVER) · Breast Neoplasms
  15. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
    Albanell J, Codony-Servat J, Rojo F, et al. · Cancer Res · 2001 · Background
    PubMed: PMID 11522647 · NCT02394496 (OVER) · Breast Neoplasms

2000 (6 papers)

  1. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.
    Takayama T, Sekine T, Makuuchi M, et al. · Lancet · 2000 · Background
    PubMed: PMID 11022927 · NCT04521153 · Carcinoma, Hepatocellular
  2. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo.
    Shim WS, Conaway M, Masamura S, et al. · Endocrinology · 2000 · Background
    PubMed: PMID 10614662 · NCT02394496 (OVER) · Breast Neoplasms
  3. Trastuzumab in CSF.
    Pestalozzi BC, Brignoli S · J Clin Oncol · 2000 · Background
    PubMed: PMID 10829059 · NCT02394496 (OVER) · Breast Neoplasms
  4. ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics.
    McPherson K, Steel CM, Dixon JM, et al. · BMJ · 2000 · Background
    PubMed: PMID 10977847 · NCT02394496 (OVER) · Breast Neoplasms
  5. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.
    Howell A, Osborne CK, Morris C, et al. · Cancer · 2000 · Background
    PubMed: PMID 10951345 · NCT02394496 (OVER) · Breast Neoplasms
  6. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
    Cobleigh MA, Vogel CL, Tripathy D, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10561337 · NCT02394496 (OVER) · Breast Neoplasms

1999 (2 papers)

  1. Biliary tract cancers.
    de Groen PC, Gores GJ, LaRusso NF, et al. · N Engl J Med · 1999 · Background
    PubMed: PMID 10536130 · NCT04720131 · Biliary Tract Neoplasms
  2. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.
    Cooper JS, Guo MD, Herskovic A, et al. · JAMA · 1999 · Background
    PubMed: PMID 10235156 · NCT06281886 · Esophageal Squamous Cell Carcinoma

1998 (8 papers)

  1. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.
    Rubin Grandis J, Melhem MF, Gooding WE, et al. · J Natl Cancer Inst · 1998 · Background
    PubMed: PMID 9625170 · NCT02394496 (OVER) · Breast Neoplasms
  2. Autocrine transforming growth factor alpha provides a growth advantage to malignant cells by facilitating re-entry into the cell cycle from suboptimal growth states.
    Jiang D, Yang H, Willson JK, et al. · J Biol Chem · 1998 · Background
    PubMed: PMID 9813060 · NCT02394496 (OVER) · Breast Neoplasms
  3. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells.
    Jeng MH, Shupnik MA, Bender TP, et al. · Endocrinology · 1998 · Background
    PubMed: PMID 9751496 · NCT02394496 (OVER) · Breast Neoplasms
  4. Aberrant regulation of transforming growth factor-alpha during the establishment of growth arrest and quiescence of growth factor independent cells.
    Howell GM, Humphrey LE, Awwad RA, et al. · J Biol Chem · 1998 · Background
    PubMed: PMID 9535913 · NCT02394496 (OVER) · Breast Neoplasms
  5. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
    Fisher B, Costantino JP, Wickerham DL, et al. · J Natl Cancer Inst · 1998 · Background
    PubMed: PMID 9747868 · NCT02394496 (OVER) · Breast Neoplasms
  6. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
    Fisher B, Bryant J, Wolmark N, et al. · J Clin Oncol · 1998 · Background
    PubMed: PMID 9704717 · NCT01309607
  7. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
    Dombernowsky P, Smith I, Falkson G, et al. · J Clin Oncol · 1998 · Background
    PubMed: PMID 9469328 · NCT02394496 (OVER) · Breast Neoplasms
  8. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
    Buzdar AU, Jonat W, Howell A, et al. · Cancer · 1998 · Background
    PubMed: PMID 9740079 · NCT02394496 (OVER) · Breast Neoplasms

1997 (1 paper)

  1. Cancer chemotherapy in older adults. A tolerability perspective.
    Kimmick GG, Fleming R, Muss HB, et al. · Drugs Aging · 1997 · Background
    PubMed: PMID 9111706 · NCT01273610 · Breast Neoplasms

1996 (3 papers)

  1. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.
    Mu J, Abe Y, Tsutsui T, et al. · Jpn J Cancer Res · 1996 · Trial result
    PubMed: PMID 8878460 · NCT03587129 · Ovarian Neoplasms
  2. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study.
    Kao YC, Cam LL, Laughton CA, et al. · Cancer Res · 1996 · Background
    PubMed: PMID 8758911 · NCT02394496 (OVER) · Breast Neoplasms
  3. Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells.
    Borrás M, Laios I, el Khissiin A, et al. · J Steroid Biochem Mol Biol · 1996 · Background
    PubMed: PMID 8645630 · NCT02394496 (OVER) · Breast Neoplasms

1995 (1 paper)

  1. Analysis of the aromatase cytochrome P450 gene in human breast cancers.
    Sourdaine P, Parker MG, Telford J, et al. · J Mol Endocrinol · 1995 · Background
    PubMed: PMID 7893351 · NCT02394496 (OVER) · Breast Neoplasms

1994 (4 papers)

  1. Karnofsky Memorial Lecture. Natural history of small breast cancers.
    Hellman S · J Clin Oncol · 1994 · Background
    PubMed: PMID 7931493 · NCT03457467 · Breast Neoplasms
  2. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.
    Encarnación CA, Ciocca DR, McGuire WL, et al. · Breast Cancer Res Treat · 1994 · Background
    PubMed: PMID 8251648 · NCT02394496 (OVER) · Breast Neoplasms
  3. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
    DeFriend DJ, Anderson E, Bell J, et al. · Br J Cancer · 1994 · Background
    PubMed: PMID 8054267 · NCT02394496 (OVER) · Breast Neoplasms
  4. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling.
    Dauvois S, White R, Parker MG, et al. · J Cell Sci · 1994 · Background
    PubMed: PMID 8126115 · NCT02394496 (OVER) · Breast Neoplasms

1992 (1 paper)

  1. Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa?
    Verger E, Salamero M, Conill C, et al. · Eur J Cancer · 1992 · Background
    PubMed: PMID 1515244 · NCT03104335 · Sarcoma

1991 (3 papers)

  1. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.
    Weidner N, Semple JP, Welch WR, et al. · N Engl J Med · 1991 · Background
    PubMed: PMID 1701519 · NCT02878057 · Breast Neoplasms
  2. A potent specific pure antiestrogen with clinical potential.
    Wakeling AE, Dukes M, Bowler J, et al. · Cancer Res · 1991 · Background
    PubMed: PMID 1855205 · NCT02394496 (OVER) · Breast Neoplasms
  3. Pulmonary metastasectomy in patients with osteosarcoma.
    van Rijk-Zwikker GL, Nooy MA, Taminiau A, et al. · Eur J Cardiothorac Surg · 1991 · Background
    PubMed: PMID 1910847 · NCT02711007 · Neoplasm Metastasis

1988 (1 paper)

  1. Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung.
    Bégin LR, Eskandari J, Joncas J, et al. · J Surg Oncol · 1988 · Background
    PubMed: PMID 2826922 · NCT03709953 (Spark-AL003) · Lung Neoplasms

1987 (1 paper)

  1. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
    Miser JS, Kinsella TJ, Triche TJ, et al. · J Clin Oncol · 1987 · Background
    PubMed: PMID 3114435 · NCT02711007 · Neoplasm Metastasis

1983 (1 paper)

  1. Multiple estrogen receptor assays in human breast cancer.
    Hull DF, Clark GM, Osborne CK, et al. · Cancer Res · 1983 · Background
    PubMed: PMID 6847780 · NCT02394496 (OVER) · Breast Neoplasms

1973 (1 paper)

  1. [Effect of the ion composition of the surrounding medium on membrane potentials of L cells].
    Potapova TV, Sharovskaia IuIu, Kovalev SA, et al. · Tsitologiia · 1973 · Trial result
    PubMed: PMID 4654530 · NCT03660761

1969 (1 paper)

  1. [The supplying of vitamin A after pancreatectomy].
    Kasper H · Med Welt · 1969 · Trial result
    PubMed: PMID 5728925 · NCT03660761

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).